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The global, regional, and national burden of cirrhosis by cause 
in 195 countries and territories, 1990–2017: a systematic 
analysis for the Global Burden of Disease Study 2017 
GBD 2017 Cirrhosis Collaborators*
Summary
Background Cirrhosis and other chronic liver diseases (collectively referred to as cirrhosis in this paper) are a major 
cause of morbidity and mortality globally, although the burden and underlying causes differ across locations and 
demographic groups. We report on results from the Global Burden of Diseases, Injuries, and Risk Factors Study 
(GBD) 2017 on the burden of cirrhosis and its trends since 1990, by cause, sex, and age, for 195 countries and territories.
Methods We used data from vital registrations, vital registration samples, and verbal autopsies to estimate mortality. 
We modelled prevalence of total, compensated, and decompensated cirrhosis on the basis of hospital and claims data. 
Disability-adjusted life-years (DALYs) were calculated as the sum of years of life lost due to premature death and years 
lived with disability. Estimates are presented as numbers and age-standardised or age-specific rates per 
100 000 population, with 95% uncertainty intervals (UIs). All estimates are presented for five causes of cirrhosis: 
hepatitis B, hepatitis C, alcohol-related liver disease, non-alcoholic steatohepatitis (NASH), and other causes. We 
compared mortality, prevalence, and DALY estimates with those expected according to the Socio-demographic Index 
(SDI) as a proxy for the development status of regions and countries.
Findings In 2017, cirrhosis caused more than 1·32 million (95% UI 1·27–1·45) deaths (440 000 [416 000–518 000; 33·3%] 
in females and 883 000 [838 000–967 000; 66·7%] in males) globally, compared with less than 899 000 (829 000–948 000) 
deaths in 1990. Deaths due to cirrhosis constituted 2·4% (2·3–2·6) of total deaths globally in 2017 compared with 1·9% 
(1·8–2·0) in 1990. Despite an increase in the number of deaths, the age-standardised death rate decreased from 
21·0 (19·2–22·3) per 100 000 population in 1990 to 16·5 (15·8–18·1) per 100 000 population in 2017. Sub-Saharan Africa 
had the highest age-standardised death rate among GBD super-regions for all years of the study period 
(32·2 [25·8–38·6] deaths per 100 000 population in 2017), and the high-income super-region had the lowest 
(10·1 [9·8–10·5] deaths per 100 000 population in 2017). The age-standardised death rate decreased or remained constant 
from 1990 to 2017 in all GBD regions except eastern Europe and central Asia, where the age-standardised death rate 
increased, primarily due to increases in alcohol-related liver disease prevalence. At the national level, the age-standardised 
death rate of cirrhosis was lowest in Singapore in 2017 (3·7 [3·3–4·0] per 100 000 in 2017) and highest in Egypt in all 
years since 1990 (103·3 [64·4–133·4] per 100 000 in 2017). There were 10·6 million (10·3–10·9) prevalent cases of 
decompensated cirrhosis and 112 million (107–119) prevalent cases of compensated cirrhosis globally in 2017. There was 
a significant increase in age-standardised prevalence rate of decompensated cirrhosis between 1990 and 2017. Cirrhosis 
caused by NASH had a steady age-standardised death rate throughout the study period, whereas the other four causes 
showed declines in age-standardised death rate. The age-standardised prevalence of compensated and decompensated 
cirrhosis due to NASH increased more than for any other cause of cirrhosis (by 33·2% for compensated cirrhosis and 
54·8% for decompensated cirrhosis) over the study period. From 1990 to 2017, the number of prevalent cases more than 
doubled for compensated cirrhosis due to NASH and more than tripled for decompensated cirrhosis due to NASH. In 
2017, age-standardised death and DALY rates were lower among countries and territories with higher SDI.
Interpretation Cirrhosis imposes a substantial health burden on many countries and this burden has increased at the 
global level since 1990, partly due to population growth and ageing. Although the age-standardised death and DALY 
rates of cirrhosis decreased from 1990 to 2017, numbers of deaths and DALYs and the proportion of all global deaths 
due to cirrhosis increased. Despite the availability of effective interventions for the prevention and treatment of 
hepatitis B and C, they were still the main causes of cirrhosis burden worldwide, particularly in low-income countries. 
The impact of hepatitis B and C is expected to be attenuated and overtaken by that of NASH in the near future. Cost-
effective interventions are required to continue the prevention and treatment of viral hepatitis, and to achieve early 
diagnosis and prevention of cirrhosis due to alcohol-related liver disease and NASH.
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Introduction 
Cirrhosis is the leading cause of liver-related death 
globally.1 It is the end stage of progressive liver fibrosis, in 
which the hepatic architecture is distorted.2 In the initial 
stages, cirrhosis is compensated. Most patients are 
asymptomatic at this stage, and cirrhosis is usually 
discovered incidentally during medical encounters for 
other reasons. Thus, reports on the prevalence of 
compensated cirrhosis are almost always underestimated. 
Decompensation in patients with compensated cirrhosis 
is usually defined as the first occurrence of ascites, 
oesophageal variceal bleeding, hepatic encephalopathy, 
and, in some individuals, increased bilirubin concen-
tration.3,4 Because of the nature of decompensation, these 
patients are rapidly brought to medical attention, and 
thus reports on the prevalence of decompensated 
cirrhosis are probably much more accurate than those of 
compensated cirrhosis.3 Once decompensation occurs, 
the mortality and morbidity resulting from cirrhosis 
increase sharply, and depending on the cause of 
decompensation, the 1-year case-fatality rate can be as 
high as 80%.5,6 Almost all of the mortality and morbidity 
resulting from cirrhosis is caused by the decompensated 
type. Such patients need frequent medical attention and 
an increasing amount of medication over the disease 
course. Quality of life is affected and frequent 
hospitalisations (admissions and stays) are required.7 
As the disease progresses, hospital stays become more 
frequent and more prolonged. Finally, patients either die 
or receive a liver transplant, which is a high-burden 
option for patients, health-care systems, and health 
financing and governance.7
Compensated cirrhosis is more benign. Patients often 
have a life expectancy similar to that of healthy adults if 
cirrhosis remains compensated.5 However, identifying 
these patients is important because if they are not treated 
appropriately, they are at risk of progressing to 
decompensated cirrhosis.3
Cirrhosis is generally considered to be irreversible at 
later stages, although reversal has been documented in 
many individuals with compensated cirrhosis after 
treating the underlying cause.8–10 The most common 
causes of cirrhosis are chronic hepatitis B and C, alcohol-
related liver disease, and non-alcoholic steatohepatitis 
(NASH).7 Patients with decompensated cirrhosis are 
susceptible to complications and a reduction in life 
expectancy.11
Despite being a global health challenge, estimates of 
cirrhosis mortality and morbidity are not widely available, 
especially at national levels, because of data sparsity in 
many regions where cirrhosis is fatal, particularly in 
Africa.12 Accurate mortality data are also scarce, because 
official death records under-report cirrhosis as a cause of 
death.13 The burden of cirrhosis differs considerably across 
locations, sexes, races and ethnicities, and socioeconomic 
strata, and the burden has also varied substantially over 
time. Moreover, the incidence and prevalence of cirrhosis 
are not well established, even in population-based studies. 
Studies are further limited by referral bias; the structure of 
the population under study (inpatient vs outpatient); 
absence of standardised definitions; and diversity in 
methods of assessment, including self-reporting, laboratory 
tests and non-invasive biomarkers, imaging, liver biopsies, 
and death certificates.12
Research in context
Evidence before this study
In 1994, an analysis of official death certification data derived 
from the WHO database was conducted, and reports were 
released on deaths due to cirrhosis from 1955 to 1990 in high-
income countries. More recently, a 2014 report on findings 
from the Global Burden of Disease Study (GBD) 2010 reported 
the mortality of cirrhosis and other chronic liver diseases in 
187 countries from 1980 to 2010. Both estimates showed 
increasing numbers and decreasing rates across almost all 
countries. Other local studies have also shown the 
contributions of vaccination and lifestyle modification to 
reductions in death rates, incidence, and prevalence of cirrhosis.
Added value of this study
In this study we present the results of the latest iteration of GBD 
(2017), regarding cirrhosis and other chronic liver diseases 
(hereafter referred to as cirrhosis). Compared with GBD 2016, 
we had access to more data points, we used novel and more 
robust methods, we made separate estimates for 
decompensated and compensated cirrhosis, and we 
differentiated non-alcoholic steatohepatitis as the fifth cause of 
cirrhosis along with hepatitis B and C, alcohol-related liver 
disease, and the broad category of other causes. Our study 
provides a valuable insight into  the shifting burden of cirrhosis 
due to different causes. Although hepatitis B caused the 
greatest proportion of cirrhosis deaths in 2017, our findings 
suggest that non-alcoholic steatohepatitis might become the 
leading cause of cirrhosis in the near future.
Implications of all the available evidence
The number of deaths and prevalent cases of both 
decompensated and compensated cirrhosis are increasing, 
despite a decrease in age-standardised death rates. The 
contribution of different causes to mortality and morbidity is 
expected to change as a result of available prevention and 
treatment modalities. Because of variation in the 
contribution of the five causes of cirrhosis assessed in this 
study and varying amounts and trends of burden across 
nations, policies should be targeted at national and even 
subnational levels accordingly. We intend for our findings 
to be used by policy makers and the public to address the 
increasing burden of chronic liver diseases.
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Data by cause are also inaccurate and diverse. 
Clarification of the underlying cause and stage of 
cirrhosis is challenging, even in high-income countries.14 
It is generally well-recognised that the contribution of 
underlying causes is variable across locations and has 
changed over time. With the availability of methods for 
controlling hepatitis B and curing hepatitis C,15 along 
with rising prevalence of metabolic syndrome and 
obesity as a plausible underlying cause, the proportion of 
cirrhosis mortality and morbidity caused by NASH is 
expected to increase in the near future.16,17
Previous studies have investigated the burden of 
cirrhosis at the global level. In 1994, La Vecchia and 
colleagues18 analysed official death certification data from 
1955 to 1990 derived from the WHO database to produce 
estimates covering 38 high-income countries. In 2014, 
Mokdad and colleagues19 reported the results of the 
2010 iteration of the Global Burden of Disease Study 
(GBD) on mortality due to cirrhosis by four causes in 
187 countries from 1980 to 2010. Both studies reported 
increasing numbers of deaths and decreasing age-
standardised mortality rates in most countries. However, 
updated estimates on mortality and morbidity caused by 
cirrhosis and the prevalence of decompensated and 
compensated types by cause were not available, to our 
knowledge, before this study. Using data from GBD 2017, 
this study provides estimates of the prevalence, mortality, 
and disability-adjusted life-years (DALYs) of cirrhosis and 
other chronic liver diseases by cause, sex, and age at 
global, regional, and national levels across 195 countries 
and territories from 1990 to 2017.
Methods
Overview
This study is part of GBD 2017,1,20–22 which was a systematic 
effort to estimate the levels and trends of burden caused 
by 359 diseases and injuries by sex, age, year (1990–2017), 
and location, including seven super-regions, 21 regions, 
and 195 countries and territories. We modelled the 
mortality and prevalence of cirrhosis and other chronic 
liver diseases, hereafter collectively referred to as 
cirrhosis. We report numbers and age-standardised and 
age-specific rates for mortality, prevalence, and DALYs, 
which are the sum of years of life lost (YLLs) due to 
premature death and years lived with disability 
(YLDs).1,20–22 This study is compliant with the Guidelines 
for Accurate and Transparent Health Estimates Reporting.
We considered diagnoses coded as B18 and K70–77 in 
the International Classification of Diseases 10th revision 
(ICD-10) to be compensated and decompensated cirrhosis. 
ICD-10 codes B18.0–18.2 were mapped to chronic viral 
hepatitis B and C in the GBD cause list, B18.8 and 18.9 to 
other causes, K70 to alcohol-related liver disease, K75.81 to 
NASH, and the rest of the codes to the category of other 
causes, which included but was not limited to autoimmune 
hepatitis (K75.4). The detailed list of ICD-10 codes mapped 
to the GBD cause list is reported in the appendix (p 4). The 
causes grouped in the “other chronic liver diseases” 
category mainly included auto immune hepatitis, toxic 
liver diseases, other inflam matory liver diseases, chronic 
hepatitis not specified, and other diseases of the liver 
(K76). ICD-10 codes for acute hepatitis were not included 
in this study. Non-alcoholic fatty liver disease was 
considered to be a separate entity from compensated and 
decompensated cirrhosis, and codes for diabetes were also 
excluded. Finally, deaths caused by hepatocellular 
carcinoma were excluded because: ICD-10 codes define 
hepatocellular carcinoma as a cause irrespective of liver 
cirrhosis; hepatocellular carcinoma can be distinguished 
from cirrhosis in countries with adequate data; and 
implications on natural history and management of the 
two causes are not similar.
Existing evidence shows that ICD-10 coding is valid for 
defining overall cirrhosis and chronic liver diseases in 
most of the data sources used to assemble the cause-of-
death database but does not have the required accuracy 
for reporting cirrhosis by the five causes estimated in the 
current study.23,24 The models that we used to split the 
parent cirrhosis mortality and morbidity into the five 
causes are described below.
Mortality estimates
Details of the methods used to estimate mortality 
have been published previously.1,20–22 We modelled decom-
pensated cirrhosis mortality due to the five causes defined 
by the aforementioned ICD-10 codes using all available 
data in the cause-of-death database. We obtained data 
from vital registrations, vital registration samples, and 
verbal autopsies. Vital registrations are systems that 
governments use to record the vital events of their 
residents, including causes of death. Vital registration 
samples are nationally representative cluster samples in 
countries where vital registration has low coverage or is 
unavailable. Verbal autopsy is a method by which causes 
of death and cause-specific mortality fractions in 
populations without a complete vital registration system 
are determined. To record data through verbal autopsy, 
trained interviewers collect information about the 
symptoms, signs, and demographic characteristics of a 
recently deceased person from an individual familiar with 
the deceased person. The majority of the cause-of-death 
data are vital registration data obtained from the WHO 
Mortality Database, which consists of data submitted to 
WHO by individual countries. Vital registration data are 
also obtained from country-specific mortality databases 
operated by official offices. We collected 19 329 data points 
from vital registrations, 793 data points from vital 
registration samples, and 1263 points from verbal 
autopsies. To address problems of zero counts in vital 
registration and verbal autopsy for a given age group in a 
given year, we used a Bayesian noise-reduction algorithm.1 
We used Cause of Death Ensemble models (CODEm) to 
estimate liver cirrhosis mortality with uncertainty by age, 
sex, country or territory, and year. CODEm is the See Online for appendix
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framework used to model most cause-specific death rates 
in GBD.1 First, all available data were identified and 
gathered. Second, a diverse set of plausible models were 
developed to capture well-documented associations in the 
estimates. The use of a wide range of individual models 
to create an ensemble predictive model has been shown 
to outperform techniques that use only a single model, 
both in cause-of-death estimation and in more general 
prediction applications.25 Third, the out-of-sample 
predictive validity was assessed for all individual models, 
which were then ranked for use in the ensemble 
modelling stage. Finally, differently weighted com-
binations of individual models were evaluated to select 
the ensemble model with the highest out-of-sample 
predictive validity.
The methods we used for propagating uncertainty are 
the same as those used in previous GBD iterations. At 
each step of the computation process, we took 1000 draws 
and then computed final estimates using the mean 
estimate across the draws. 95% uncertainty intervals 
(UIs) were calculated as the 25th and 975th ranked values 
across all 1000 draws.
In GBD 2017, NASH was included as a fifth cause of 
cirrhosis for the first time. Cirrhosis caused by NASH 
was previously nested within the category of other 
cirrhosis. As discussed previously, we were able to use 
the cause-of-death database only for estimating overall 
cirrhosis and not its five causes. Instead, we used 
DisMod-MR 2.1 to split the parent cirrhosis mortality 
estimates and used liver cancer aetiological proportion 
models as covariates. These covariates included alcohol 
consumption (L per capita), HBsAg seroprevalence, 
hepatitis C (anti-hepatitis C virus antibody) sero-
prevalence, and obesity. Proportions from the five 
aetiological models were then rescaled to sum to one at 
the draw level and used to split the parent cirrhosis 
mortality estimates.
Morbidity estimates 
We modelled total cirrhosis prevalence and decom-
pensated and compensated cirrhosis on the basis of 
hospital data and claims data, using different definitions 
for each model. Total cirrhosis prevalence was defined 
as any diagnosis of cirrhosis. The distinction between 
decompensated and compensated cirrhosis was based 
on the diagnosis made upon hospital admission. If 
cirrhosis was the primary diagnosis upon hospital 
admission, we considered the case to be decompensated. 
If cirrhosis was diagnosed in outpatient settings or was 
detected among patients admitted to the hospital for 
other causes, we considered the case to be compensated.
A systematic review of the literature was done to 
identify studies on the proportion of cirrhosis cases 
attributable to alcohol-related liver disease, hepatitis B, 
hepatitis C, NASH, and other causes. We re-extracted all 
literature within our databases on cirrhosis cause 
proportions for cirrhosis due to NASH. We searched the 
peer-reviewed literature via PubMed and solicited sources 
from GBD 2017 collaborators. The inclusion criteria 
stipulated that the publication year was 1980 or later; the 
sample was representative of patients with decompensated 
cirrhosis (eg, studies of patients with both hepatocellular 
carcinoma and hepatitis were excluded); sufficient 
information was provided on study method and sample 
characteristics to assess the quality of the study; and 
hepatitis B and C were confirmed via HBsAg in the case 
of hepatitis B, and anti-hepatitis C virus antibody in the 
case of hepatitis C. The number of site-years of data by 
cause is provided in the appendix (p 4).
We modelled cirrhosis prevalence using hospital data 
and cause-specific mortality rates, assuming no 
remission.20 Similar to the mortality estimates, we 
developed aetiological proportion models using DisMod-
MR 2.1 and used the results of these models to split the 
parent total cirrhosis prevalence estimates. We adopted 
the aetiological proportion model from liver cancer. We 
first developed five single-parameter DisMod models, 
each to estimate the proportion of liver cancer due to a 
given cause (ie, alcohol, hepatitis B, hepatitis C, NASH, 
and other). Estimates from these liver cancer models 
were then used as covariates in the five corresponding 
cirrhosis aetiological models. Proportions from the 
five aetiological models were then rescaled to sum to one 
at the draw level and used to split the parent cirrhosis 
estimates. We multiplied these fractions by prevalence 
separately for decom pensated and compensated 
cirrhosis by age, sex, year, and location, and estimated 
the prevalence due to cirrhosis by each cause. Upon 
calculation of cause fractions, we encountered some 
reports on cirrhosis due to more than one cause. In 
these cases, we redistributed the numbers proportionally 
on the number of cases diagnosed with only one cause.
To calculate YLDs, prevalence was multiplied by a 
disability weight, which represents the magnitude of the 
health loss associated with disease. Disability weights are 
measured on a scale from 0 to 1, where 0 is a state of full 
health and 1 is death. Compensated cirrhosis has a 
disability weight of 0 because of its asymptomatic nature. 
Decompensated cirrhosis from any cause has a disability 
weight of 0·178 (95% UI 0·122–0·250).20
We used the Socio-demographic Index (SDI) to 
determine the relationship between the development level 
of a region or country and cirrhosis mortality, prevalence, 
and DALYs. In GBD 2017, the SDI was revised to better 
reflect the development status of each country. The SDI 
ranges from 0 (worst) to 1 (best) and is a composite 
measure of the total fertility rate in women under the age 
of 25 years, mean education for individuals aged 15 years 
and older, and lag-distributed income per capita.
All estimates are reported in terms of counts, rates 
per 100 000 population, and percentages. Population 
estimates independently produced by GBD 2017 were used 
as references for calculating age-standardised death rates 
and age-standardised prevalence.26 95% UIs, including all 
Articles
www.thelancet.com/gastrohep   Published online January 22, 2020    https://doi.org/10.1016/S2468-1253(19)30349-8 5
sources of uncertainty arising from measurement error, 
systematic biases, and modelling, are reported for all 
estimates. All estimates of mortality, prevalence, DALYs, 
YLDs, and YLLs are reported by sex and age, and across 
location and time period studied (1990–2017).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or the 
writing of the report. The corresponding authors had full 
access to the data in the study and had final responsibility 
for the decision to submit for publication.
Results
Globally, cirrhosis caused more than 1·32 million 
(95% UI 1·27–1·45) deaths in 2017, with 440 000 deaths 
(416 000–518 000; 33·3%) in females and 883 000 
(838 000–967 000; 66·7%) in males, compared with less 
than 899 000 (829 000–948 000) deaths for both sexes in 
1990 (figure 1; appendix p 5). These deaths constituted 
2·4% (2·3–2·6) of all deaths globally in 2017 compared 
with 1·9% (1·8–2·0) in 1990. The age-standardised 
death rate at the global level decreased from 21·0 
(19·2–22·3) per 100 000 population in 1990 to 16·5 
(15·8–18·1) per 100 000 population in 2017 (figure 1). 
The age-standardised death rate was consistently lowest 
in the high-income super-region (10·1 [9·8–10·5] per 
100 000 in 2017) and highest in the sub-Saharan Africa 
super-region (32·2 [25·8–38·6] per 100 000 in 2017) in 
all years from 1990 to 2017 (appendix p 237). The pattern 
of age-standardised death rates between 1990 and 2017 
was similar in males and females, although the rates 
were consistently higher in males than females in all 
super-regions (estimates available through the GBD 
online results tool and data visualisation tool) and all 
years from 1990 to 2017 (figure 1).
Cirrhosis led to nearly 41·4 million (95% UI 39·6–45·1) 
DALYs in 2017, which was an increase from just over 
30·5 million (28·6–32·2) in 1990. The age-standardised 
rate of DALYs decreased from 656·4 (612·8–689·2) per 
100 000 population in 1990 to 510·7 (487·6–557·1) per 
100 000 population in 2017 (appendix p 15). In 2017, 
cirrhosis caused 28·8 million DALYs (27·3–31·4) in 
males and 12·6 million DALYs (11·9–14·7) in females, 
compared with 20·6 million DALYs (18·7–21·8) in males 
and 9·9 million (9·1–11·1) DALYs in females in 1990. The 
age-standardised DALY rates in 2017 were 719·3 
(683·0–784·9) per 100 000 population in males and 307·6 
(288·5–359.6) per 100 000 in females, which was a 
substantial decrease from 1990 (903·1 [820·1–956·1] per 
100 000 in males and 415·5 [382·5–457·1] per 100 000 in 
females in 1990; estimates available through the GBD 
online results tool).
The number of prevalent cases of decompensated 
cirrhosis globally increased from more than 
5·20 million (95% UI 5·08–5·32) in 1990 to over 
10·6 million (10·3–10·9) in 2017 (appendix p 23), of 
which 6·42 million (6·23–6·60; 60·3%) prevalent cases 
were in males and 4·23 million (4·10–4·35; 39·7%) 
were in females (data not shown). The age-standardised 
prevalence of decompensated cirrhosis increased 
from 110·6 (108·0–113·0) per 100 000 population in 
1990 to 132·5 (128·6–136·2) per 100 000 population in 
2017 (appendix p 23). In males, the age-standardised 
prevalence in 2017 was 162·7 (157·9–167·3) per 100 000, 
with a 21·1% (19·7–22·4) increase from 1990 to 2017. In 
females, the age-standardised prevalence in 2017 was 
103·5 (100·6–106·3) per 100 000, with an 18·1% 
Figure 1: Counts and age-standardised rates of cirrhosis death at the global level by sex, 1990–2017
Error bars indicate 95% UIs for number of deaths. Shading indicates 95% UIs for age-standardised death rates. UI=uncertainty interval.
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(16·9–19·2) increase from 1990 to 2017 (data not 
shown).
The number of global prevalent cases of compensated 
cirrhosis increased from 65·9 million (95% UI 63·4–68·7) 
in 1990 to just over 112 million (107–119) in 2017 
(appendix p 32), of which 66·1 million (62·7–69·7; 58·8%) 
prevalent cases were in males and 46·3 million (43·8–48·8; 
41·2%) were in females (data not shown). The age-
standardised prevalence of compensated cirrhosis 
increased from 1354·5 (1300·6–1411·7) per 100 000 in 
1990 to 1395·0 (1323·5–1470·5) in 2017 (appendix p 32).
The age-standardised prevalence of compensated 
cirrhosis in males was 1605·4 (95% UI 1543·3–1671·2) 
per 100 000 in 1990 and 1651·4 (1567·5–1742·8) per 
100 000 in 2017. The age-standardised prevalence of 
compensated cirrhosis in females was 1103·3 
(1055·6–1152·4) per 100 000 in 1990 and 1142·4 
(1079·9–1204·0) per 100 000 in 2017 (data not shown). 
Figure 2: Age-standardised rates for cirrhosis by region and sex, 2017
(A) Age-standardised death rate. (B) Age-standardised prevalence rate of compensated and decompensated cirrhosis. Error bars indicate 95% uncertainty intervals 
for age-standardised rates.
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The percentage change in age-standardised prevalence 
rate of compensated cirrhosis from 1990 to 2017 was 
2·9% (0·4–5·2) in males and 3·5% (1·3–5·6) in females 
(data not shown).
At the regional level, central Asia had the highest age-
standardised death rate due to cirrhosis in 2017 for males, 
females, and both sexes combined (39·0 [95% UI 
36·2–41·5] per 100 000 for both sexes combined; figure 2A), 
with deaths largely driven by alcohol-related liver disease 
(36·6% of all cirrhosis deaths). Western, eastern, and 
central sub-Saharan Africa had the next highest age-
standardised death rates for both sexes combined in 2017, 
with rates of 35·8 (23·9–49·9) per 100 000 population in 
western Africa, 34·8 (26·4–42·2) per 100 000 population in 
eastern Africa, and 34·3 (25·9–45·2) per 100 000 population 
in central sub-Saharan Africa (figure 2A). In central and 
eastern sub-Saharan Africa in 2017, the most common 
cause of death due to cirrhosis was hepatitis C (32·4% and 
28·9%, respectively), followed by hepatitis B (31·2% and 
25·9%, respectively; appendix p 41). However, in western 
sub-Saharan Africa, the most common cause of death due 
to cirrhosis was hepatitis B (48·9%) in all countries in the 
region, whereas the proportion of deaths from hepatitis C 
was much lower in this region (7·8%) than in the other 
sub-Saharan African regions (appendix p 41).
Southeast Asia ranked fifth in terms of age-standardised 
death rate from cirrhosis across regions in 2017 (29·5 
[95% UI 27·7–31·9] per 100 000) but had low age-
standardised prevalence rates of compensated and 
decompensated cirrhosis (figure 2A, B); both deaths and 
prevalent cases were mainly caused by hepatitis B and C 
(appendix pp 41, 48, 55).
Eastern Europe ranked sixth in terms of age-
standardised death rate due to cirrhosis in 2017 
(25·9 [95% UI 25·0–26·7] per 100 000), and, as in central 
Asia, deaths were primarily caused by alcohol-related 
liver disease (figure 2A; appendix pp 5, 41). These two 
regions were the only ones in which age-standardised 
death rates significantly increased over the study period: 
by 137·0% (129·5–146·2) in eastern Europe and by 
50·5% (38·6–59·9) in central Asia (appendix p 5). The 
age-standardised death rate increased by more than 100% 
in all but one country (Moldova) in eastern Europe 
(appendix p 5). Eastern Europe had a high and increasing 
age-standardised prevalence of both decompensated and 
compensated cirrhosis from 1990 to 2017; prevalent cases 
were predominantly caused by alcohol-related liver 
disease (figure 2B; appendix pp 48, 55).
The age-standardised death rate was lowest in 
Australasia (5·4 [95% UI 4·9–6·0] per 100 000 population), 
east Asia (8·3 [7·6–10·7] per 100 000 population), and 
high-income Asia Pacific (8·6 [7·9–9·1] per 
100 000 population; figure 2A). Australasia was among 
the regions with the lowest age-standardised prevalence 
of both compensated and decompensated cirrhosis 
(figure 2B). Deaths due to cirrhosis and prevalent cases 
of compensated and decompensated cirrhosis in this 
region were primarily caused by hepatitis C 
(appendix pp 48, 55). East Asia had the second-lowest 
age-standardised death rate, but it had a relatively high 
age-standardised prevalence rate for compensated and 
decompensated cirrhosis combined (figure 2A, B). 
Deaths due to cirrhosis and prevalent cases of 
compensated and decompensated cirrhosis in this region 
were driven primarily by hepatitis B (appendix pp 41, 48, 55).
High-income Asia Pacific had the third lowest age-
standardised death rate in 2017 and all countries in this 
region experienced a steep decline over the study period, 
particularly South Korea (figure 2A; appendix p 5). 
However, this region had the highest age-standardised 
prevalence for both compensated cirrhosis (2455·0 
[95% UI 2344·9–2575·8] per 100 000) and decompensated 
cirrhosis (267·4 [259·8–275·1] per 100 000) in 2017 
(figure 2B). The high age-standardised prevalence in this 
region was primarily driven by high numbers of prevalent 
cases in Japan, where the highest proportions of 
compensated and decompensated cirrhosis were due to 
hepatitis C (appendix pp 23, 32, 48, 55).
Western Europe, southern sub-Saharan Africa, and 
high-income North America had the fourth to sixth 
lowest age-standardised death rates of cirrhosis in 2017 
(figure 2A; appendix p 5). In western Europe, deaths 
were primarily caused by alcohol-related liver disease 
(41·7%), whereas in southern sub-Saharan Africa and 
high-income North America, deaths were primarily 
caused by hepatitis C (33·9% and 34·7%, respectively; 
appendix p 41). Western Europe and southern sub-
Saharan Africa had modest age-standardised prevalence 
rates of both compensated and decompensated cirrhosis, 
whereas high-income North America had the lowest age-
standardised prevalence of compensated cirrhosis of all 
regions; prevalent cases in this region were mainly 
caused by hepatitis C (figure 2B; appendix pp 48, 55).
South Asia and Oceania had modest age-standardised 
death rates but were among the regions with the lowest 
age-standardised prevalence of compensated and 
decompensated cirrhosis (figure 2A, B). Deaths due to 
cirrhosis and prevalent cases of compensated and 
decompensated cirrhosis were primarily caused by 
hepatitis B in these regions (appendix p 41).
Central Latin America was among the regions with the 
highest age-standardised prevalence of both compensated 
(2272·3 [95% UI 2167·0–2383·4] per 100 000) and 
decompensated (206·6 [200·4–212·6] per 100 000) 
cirrhosis (figure 2B; appendix pp 23, 32), although age-
standardised death rates were modest in this region. 
Other regions in Latin America had modest age-
standardised death rates and age-standardised prevalence 
rates of both types of cirrhosis. Cirrhosis deaths in Latin 
American regions were primarily driven by alcohol-
related liver disease, except for tropical Latin America 
(38·1% in Andean Latin America, 36·6% in central Latin 
America, 34·8% in the Caribbean, and 34·6% in 
southern Latin America; appendix p 41). Cirrhosis deaths 
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in tropical Latin America were mainly attributable to 
hepatitis C. In every Latin American region, the cause of 
the highest proportion of cirrhosis deaths was also the 
cause of the highest proportion of compensated and 
decompensated cirrhosis prevalent cases (appendix 
pp 48, 55).
Finally, north Africa and the Middle East had modest 
age-standardised death and prevalence rates from 
cirrhosis, with the largest proportion of deaths due to 
cirrhosis and prevalent cases of compensated and 
decompensated cirrhosis driven by hepatitis B and C.
Specific country and territory data can be found in the 
appendix (pp 5–14 for age-standardised death rates; 
pp 15–22 for DALYs, pp 23–40 for prevalence, and 
pp 41–68 for cause). Egypt had the highest age-
standardised death rate of cirrhosis in all years from 
1990 to 2017, despite a 22·4% (95% UI 1·5–42·1) decrease 
from 1990 (133·1 [76·4–150·8] per 100 000) to 2017 (103·3 
[64·4–133·4] per 100 000). The second highest rate was in 
Rwanda in 1990 (88·1 [71·9–104·8] per 100 000) and in 
Cambodia in 2017 (79·4 [67·4–96·1] per 100 000; 
figure 3A; appendix p 5). In 2017, 41·5% of deaths due to 
cirrhosis in Egypt were caused by hepatitis B and 34·4% 
were caused by hepatitis C (appendix p 41).
The lowest age-standardised death rate of cirrhosis in 
2017 was in Singapore (3·7 [95% UI 3·3–4·0] per 
100 000 population). The largest increase in age-
standardised death rate from 1990 to 2017 was in 
Lithuania (176·7% [154·1–203·2]; appendix p 5). The 
eight countries with the largest increases in age-
standardised death rate from cirrhosis over the study 
period (in order: Lithuania, Ukraine, Belarus, Russia, 
Kazakhstan, Estonia, Latvia, and Armenia) were all in 
eastern Europe or central Asia (appendix p 5). In all of 
these countries, the largest proportion of deaths in 2017 
was caused by alcohol-related liver disease (appendix p 41).
Among the ten countries with the highest age-
standardised prevalence of decompensated cirrhosis in 
2017, eight were from central and eastern Europe (in order: 
Slovakia [349·6, 95% UI 338·4–361·2] per 100 000, 
Moldova, Romania, Poland, Ukraine, Lithuania, Albania, 
and Hungary), in addition to Japan (third-highest; 279·8 
[272·0–287·8] per 100 000) and South Korea (eighth-
highest; 245·9 [237·8–253·9] per 100 000; figure 3B; 
appendix p 23). The Philippines had the lowest age-
standardised prevalence of decompensated cirrhosis in 
2017 (41·8 [40·2–43·4 per 100 000 population]), with the 
largest proportion of prevalent cases due to hepatitis B.
Figure 3: Age-standardised death rate for cirrhosis in 2017 (A), age-standardised prevalence for decompensated cirrhosis (B), and age-standardised prevalence for compensated cirrhosis (C), 
2017
ATG=Antigua and Barbuda. FSM=Federated States of Micronesia. Isl=Islands. LCA=Saint Lucia. TLS=Timor-Leste. TTO=Trinidad and Tobago. VCT=Saint Vincent and the Grenadines.
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Despite decreasing age-standardised prevalence of 
compensated cirrhosis since 1990, South Korea and 
Japan were among the ten countries with the highest 
rates in 2017 (figure 3C; appendix p 32). The three 
countries or territories with the highest age-standardised 
prevalence of compensated cirrhosis were Moldova, 
Taiwan (Province of China), and Slovakia.
Globally, in 2017, 31·5% of cirrhosis deaths in males 
were caused by hepatitis B, 25·5% were caused by 
hepatitis C, 27·3% were caused by alcohol-related liver 
disease, 7·7% were caused by NASH, and 8·0% resulted 
from other causes. In females, the proportions of 
cirrhosis deaths caused by hepatitis B (24·0%) and 
alcohol-related liver disease (20·6%) were lower than in 
males, the proportion caused by hepatitis C (26·7%) was 
similar to that in males, and the proportion caused by 
NASH (11·3%) and by other causes (17·3%) was higher 
than in males (figure 4).
Hepatitis B caused around 287 000 (95% UI 
252 000–318 000) deaths due to cirrhosis in 1990, which 
increased to almost 384 000 (349 000–442 000) in 2017. 
278 000 (252 000–321 000; 72·5%) of these deaths in 2017 
occurred in males, and 106 000 (94 000–130 000; 27·5%) 
occurred in females (appendix p 69). However, the age-
standardised death rate for both sexes combined 
decreased steadily from 6·7 (5·8–7·4) per 100 000 in 1990 
to 4·8 (4·3–5·5) per 100 000 in 2017 (figure 5; 
appendix p 69). The age-standardised death rate of 
cirrhosis due to hepatitis B was 7·2 (6·5–8·3) per 
100 000 in males and 2·5 (2·2–3·1) per 100 000 in females 
in 2017. Hepatitis B caused 36·7 million (95% UI 
34·1–39·5) prevalent cases of compensated cirrhosis and 
2·97 million (2·81–3·12) cases of decompensated 
cirrhosis in 2017. The age-standardised prevalence of 
decompensated cirrhosis caused by hepatitis B increased 
from 30·9 (95% UI 29·3–32·2) per 100 000 in 1990 to 
36·6 (34·7–38·4) per 100 000 in 2017 (appendix p 139). 
The age-standardised prevalence of compensated 
cirrhosis caused by hepatitis B did not change notably 
from 1990 (461·8 [435·8–491·2] per 100 000) to 2017 (451·9 
[95% UI 420·0–485·9] per 100 000; appendix p 184). 
Across regions, the proportion of deaths from cirrhosis 
due to hepatitis B was highest in western sub-Saharan 
Africa (48·9%) and lowest in high-income North America 
(5·7%; figure 4). The proportion of cirrhosis mortality 
that was caused by hepatitis B ranged from 5·7% in 
the USA to 54·8% in Chad (appendix pp 41).
Hepatitis C caused more than 225 000 (95% UI 
202 000–249 000) cirrhosis deaths in 1990, which 
increased to over 342 000 (313 000–381 000) in 2017. 
225 000 (203 000–251 000; 65·8%) of these deaths in 2017 
occurred in males, and 117 000 (107 000–135 000; 34·2%) 
occurred in females (appendix p 83). The age-standardised 
death rate decreased from 5·3 (4·8–5·9) per 100 000 in 
Figure 4: Proportion of deaths due to five causes of cirrhosis at global and regional levels by sex, 2017
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1990 to 4·2 (3·9–4·7) per 100 000 in 2017 (figure 5; 
appendix p 83). The age-standardised death rate due to 
hepatitis C was 5·8 (5·3–6·5) per 100 000 in males and 
2·8 (2·5–3·2) in females in 2017. Hepatitis C caused 
27·72 million (25·52–30·00) cases of compensated 
cirrhosis and 2·64 million (2·49–2·81) cases of decom-
pensated cirrhosis in 2017. The age-standardised 
prevalence of compensated cirrhosis caused by hepatitis C 
was 327·0 (303·9–349·7) per 100 000 in 1990 and 341·1 
(314·1–368·7) per 100 000 in 2017. The age-standardised 
prevalence of decompensated cirrhosis increased from 
27·2 (25·7–28·7) per 100 000 in 1990 to 32·5 (30·6–34·5) 
per 100 000 in 2017 (appendix pp 148, 193). Generally, the 
lowest proportions of cirrhosis mortality due to hepatitis 
C were observed in countries in western sub-Saharan 
Africa (7·8%) and the highest among countries in high-
income Asia-Pacific (41·3%; figure 4). The proportion of 
cirrhosis mortality that was caused by hepatitis C ranged 
from 7·1% in Niger to 55·7% in Tunisia (appendix p 41).
Alcohol-related liver disease caused just over 215 000 
(95% UI 195 000–235 000) cirrhosis deaths in 1990, which 
increased to just over 332 000 (303 000–373 000) deaths in 
2017. 241 000 (220 000–268 000; 72·6%) of these deaths in 
2017 occurred in males, and 91 000 (82 000–110 000; 27·4%) 
occurred in females. The age-standardised death rate 
decreased from 5·1 (4·6–5·5) per 100 000 in 1990 to 4·1 
(3·7–4·6) per 100 000 in 2017 (figure 5; appendix p 97). The 
age-standardised death rate due to alcohol-related liver 
disease was 6·2 (5·7–6·9) per 100 000 in males and 2·1 
(1·9–2·6) per 100 000 in females in 2017. Alcohol-related 
liver disease caused 23·6 million (21·9–25·5) cases of 
compensated cirrhosis and 2·46 million (2·32–2·61) cases 
of decompensated cirrhosis in 2017. The age-standardised 
prevalence of decompensated cirrhosis caused by alcohol-
related liver disease increased from 25·3 (23·9–26·7) per 
100 000 in 1990 to 30·0 (28·2–31·8) per 100 000 in 2017. 
The age-standardised prevalence of compensated cirrhosis 
caused by alcohol-related liver disease did not change 
notably from 1990 (290·0 [271·9–309·9] per 100 000) to 
2017 (288·1 [267·5–311·3] per 100 000; appendix pp 157, 
202). Among GBD regions, the highest proportions of 
cirrhosis deaths due to alcohol-related liver disease were 
in central Europe (44·0%), western Europe (41·7%), and 
Andean Latin America (38·1%; figure 4; appendix p 41). 
The proportion of cirrhosis deaths due to alcohol-related 
liver disease was lowest in north Africa and the Middle 
East (5·3%) and in Egypt specifically (4·8%), and highest 
in Belgium (53·5%; appendix p 41).
NASH caused almost 61 900 (95% UI 55 400–68 000) 
cirrhosis deaths in 1990, which increased to around 
118 000 (109 000–129 000) in 2017. 68 000 (62 000–75 000; 
57·6%) of these deaths in 2017 occurred in males, and 
50 000 (46 000–56 000; 42·4%) occurred in females. NASH 
was the only cause for which the age-standardised death 
rate did not decrease: the rate was 1·5 (1·3–1·6) per 
100 000 in 1990 and 1·5 (1·3–1·6) per 100 000 in 2017 
(figure 5; appendix p 111). The age-standardised death rate 
due to NASH was 1·8 (1·6–1·9) per 100 000 in males and 
1·2 (1·1–1·3) per 100 000 in females in 2017. NASH caused 
4·06 million (3·70–4·45) prevalent cases of compensated 
Figure 5: Number of deaths and age-standardised death rates at the global level by cause of cirrhosis, 1990–2017
Bars refer to number of deaths in each year. Lines refer to age-standardised death rate in each year. NASH=non-alcoholic steatohepatitis.
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Figure 6: Age patterns of 
deaths, DALYs, and 
prevalence of cirrhosis by 
sex, 2017
(A) Number of deaths and 
age-specific death rate per 
100 000 population. 
(B) Number of DALYs and age-
specific DALY rate per 
100 000 population. 
(C) Number of prevalent cases 
and age-specific prevalence 
rates per 100 000 population 
of decompensated and 
compensated cirrhosis. Error 
bars indicate 95% UIs for 
number of deaths, DALYs, and 
prevalent cases. Shading 
indicates 95% UIs for death 
rates, DALY rates, and 
prevalence rates. 
DALYs=disability-adjusted life-
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cirrhosis in 1990 and 9·42 million (8·57–10·34) cases in 
2017 (more than doubling over the study period). NASH 
caused 325 000 (302 000–349 000) cases of decompensated 
cirrhosis in 1990 and 917 000 (850 000–986 000) cases in 
2017 (nearly tripling over the study period). The age-
standardised prevalence of compensated cirrhosis caused 
by NASH increased from 86·7 (79·0–94·6) per 100 000 in 
1990 to 115·5 (105–126·5) per 100 000 in 2017, a 33·2% 
increase. The age-standardised prevalence of decom-
pensated cirrhosis increased from 7·3 (6·8–7·8) per 
100 000 in 1990 to 11·3 (10·4–12·1) per 100 000 in 2017, a 
54·8% increase (appendix pp 166, 211). At the regional 
level, the proportion of deaths due to NASH was highest 
in Latin American regions, with the highest proportion in 
Tropical Latin America (22·6%) and Andean Latin 
America (22·2%). The lowest proportion was in high-
income Asia Pacific (4·7%; figure 4; appendix p 41). At the 
national level, the proportion of deaths due to NASH was 
highest in Ecuador (25·2%) and lowest in Singapore 
(2·7%).
Finally, other causes led to almost 110 000 (95% UI 
97 000–127 000) cirrhosis deaths in 1990, which increased 
to around 146 000 (131 000–165 000) in 2017. 70 000 
(62 000–80 000; 48·0%) of these deaths in 2017 occurred 
in males, and 76 000 (67 000–90 000) occurred in females 
(52·0%). The age-standardised death rate decreased from 
2·5 (2·2–2·8) per 100 000 in 1990 to 1·9 (1·7–2·1) per 
100 000 in 2017 (figure 5; appendix p 125). Other causes 
led to 15·0 million (13·6–16·2) cases of compensated 
cirrhosis and 1·65 million (1·55–1·76) cases of 
decompensated cirrhosis in 2017. The age-standardised 
prevalence of decompensated cirrhosis due to other 
causes was 20·0 (18·9–21·1) per 100 000 population  in 
1990 and 22·2 (20·9–23·5) per 100 000 in 2017. The age-
standardised prevalence of compensated cirrhosis due to 
other causes was 189·0 (173·0–204·6) per 100 000 
population in 1990 and 198·4 (180·1–215·4) per 100 000 
in 2017 (appendix pp 175, 220). At the regional level, the 
proportion of deaths due to other causes of cirrhosis was 
highest in high-income North America (20·6%) and 
lowest in east Asia (3·8%; figure 4; appendix p 41). At the 
national level, the highest proportion of deaths was in 
the UK (30·0%) and the lowest was in China (3·8%) and 
the United Arab Emirates (3·8%).
Patterns in burden by age were similar between males 
and females and across years from 1990 to 2017, although 
the numbers and rates were consistently higher in males 
than in females. The number of deaths peaked at 
60–64 years in both sexes combined in the years 
1990–2004 and 2011–17, and at 55–59 years for all other 
years (estimates available through the GBD results tool). 
In 2017, the number of deaths peaked in the 
60–64 year age group for males and the 65–69 year age 
group for females, whereas death rates increased steadily 
with age in every year of the study period (figure 6A). 
In 2017, the number of DALYs peaked at 50–54 years in 
males and at 55–59 years in females, whereas DALY rates 
peaked at 60–64 years in males and 70–74 years in females 
(figure 6B). The number of prevalent cases of compensated 
cirrhosis peaked at 45–49 years in females and 
40–44 years in males in 2017. The prevalence rate of 
compensated cirrhosis peaked at 45–49 years in males and 
at 50–54 years in females. The number of prevalent cases 
of decompensated cirrhosis peaked at 50–54 years in both 
sexes, whereas the prevalence rates increased up to 
65–69 years for males and 75–79 years for females, 
decreased until 90–94 years for males before increasing 
again, and decreased through the oldest age groups for 
females (figure 6C).
Age patterns across regions are provided in the 
appendix (pp 241–61). In high-income North America 
in 2017, the number of deaths was highest in the age 
groups from 50 to 69 years for both sexes combined, 
with an increasing trend in both the number and rate of 
deaths in these age groups from 1990 to 2017. In both 
1990 and 2017, death rates increased with age, up to and 
including the 95 years and older age group. The number 
of cirrhosis deaths in 2017 was also highest in the 
middle-aged age groups (50–74 years) in all other 
regions except Oceania (highest in the 40–55 year age 
groups) and high-income Asia Pacific (highest in the 
75–84 year age groups). However, unlike high-income 
North America, these regions, with the exception of 
eastern Europe, all experienced a decreasing trend in 
death rates in the middle-aged age groups over the 
study period.
The age patterns in central and eastern Europe were 
markedly different from other regions. Although the 
number of deaths in these regions peaked at 55–69 years 
in 2017, similar to other regions, death rates did not 
consistently increase with age. In 2017, death rates in 
central Europe declined from 70–74 years to 90–94 years, 
and in eastern Europe from 65–69 years to 80–84 years 
and increased again in the oldest age groups in both 
regions. In all other regions, death rates increased with 
increasing in age in all years from 1990 to 2017.
Between 1990 and 2017, the age-standardised death rate 
decreased or remained steady in all regions except central 
Asia and eastern Europe (figure 7A). In these two regions, 
the observed age-standardised death rates not only 
increased over the study period, but increased to much 
higher rates than those that would be expected based 
solely on SDI. The observed trend in these two regions 
was an increase in age-standardised death rate from 
1990 to the late 2000s, then a slight decrease until 2017. 
Overall, the age-standardised death rate was lower at the 
regional level at higher SDI levels, with expected rates 
following a roughly linear decreasing trend until SDI 
equalled 0·70, an increase in age-standardised death rate 
until an SDI of 0·75, then a decline through the highest 
SDI levels. High and increasing rates in eastern Europe 
explain the rise in expected rates at 0·70 SDI. At the 
national level, age-standardised death rates were also 
lower at higher SDI levels in 2017 (appendix p 262).
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Figure 7 continues on next page
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Figure 7: Age-standardised rates of cirrhosis globally and for 21 regions by SDI, 1990–2017
(A) Age-standardised death rate per 100 000 population. (B) Age-standardised DALY rate per 100 0000 population. (C) Age-standardised prevalence per 100 000 population of decompensated 
cirrhosis. (D) Age-standardised prevalence per 100 000 population of compensated cirrhosis. For each region, points from left to right depict estimates from each year from 1990 to 2017. Black lines 
show the expected death, DALY, or prevalence rates on the basis of SDI alone. DALYs=disability-adjusted life-years. SDI=Socio-demographic Index.
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The patterns of age-standardised DALY rates versus 
SDI were similar to those of age-standardised death rates 
(figure 7B; appendix p 262). In most regions, the observed 
age-standardised death and DALY rates were close to 
their expected value on the basis of SDI. The exceptions 
were western sub-Saharan Africa, southeast Asia, central 
Asia, and central Latin America, where observed levels 
were higher than expected in every year of the study 
period.
Age-standardised prevalence of decompensated 
cirrhosis was slightly higher at higher SDI levels, although 
it decreased at an SDI of 0·45 (because of low age-
standardised prevalence in Oceania and south Asia) and 
peaked at an SDI of 0·75 (because of high age-standardised 
prevalence in central and eastern Europe; figure 7C). 
Southern sub-Saharan Africa was the only region where 
age-standardised prevalence of decom pensated cirrhosis 
decreased over time. The pattern of compensated cirrhosis 
versus SDI was similar to that of decompensated cirrhosis, 
although most regions showed little change in rate over 
time. The high-income Asia Pacific region showed a 
decline in age-standardised prevalence of compensated 
cirrhosis over the study period, but it was still much 
higher than expected based on SDI (figure 7D).
Discussion
In this paper, we described the results of GBD 2017 
regarding cirrhosis mortality and morbidity by the 
four most common causes, and a fifth category of other 
causes. Of note, the four major causes of cirrhosis 
mortality and morbidity can generally be prevented by 
vaccination or lifestyle modification and are readily 
treatable if diagnosed early enough.7 It is essential for 
national health-care policy makers to know the death and 
prevalence rates of each cause to be able to plan and 
implement systematic interventions that prevent 
premature deaths and morbidity due to cirrhosis.
The age-standardised death, DALY, and prevalence 
rates were universally lower in females than in males in 
both 1990 and 2017. Generally, females had a lower 
proportion of cirrhosis deaths caused by hepatitis B and 
alcohol-related liver disease than males, and had a higher 
proportion due to NASH and other causes. This trend 
could be driven by hormonal factors; lower prevalence of 
high-risk behaviours; higher prevalence of obesity;27 
lower consumption of alcohol;28 and diseases that almost 
exclusively affect women, such as autoimmune hepatitis, 
which has a simple and effective treatment and low 
mortality if treated in time.29
Our results show that in almost all regions, the number 
of deaths peaked in the middle-aged age groups 
(approximately 50–74 years) and rates increased steadily 
with increasing age. Central and eastern Europe were 
exceptions to these trends, and showed lower death rates 
in the older age groups (approximately 70–84 years) than 
in the middle-aged age groups throughout the study 
period. These findings suggest that cirrhosis incidence 
in these regions, where cirrhosis deaths are primarily 
driven by alcohol-related liver disease, was higher in the 
1990s, coinciding with peak consumption of alcohol 
following the dissolution of the Soviet Union, than in 
2017.28,30 Among high-income regions, high-income North 
America showed an unusual age pattern, with an 
increase in death rates in the 50–69 year age group from 
1990 to 2017. This finding is compatible with previous 
reports for the USA and Canada.31,32
Our results show that the numbers of deaths and 
DALYs due to cirrhosis increased globally between 
1990 and 2017. The increase in numbers was primarily 
driven by population growth and ageing across the globe, 
specifically in low-income and middle-income countries.26 
By contrast, age-standardised death and DALY rates 
decreased, and were lower at higher SDI levels. 
Accordingly, we observed high age-standardised death 
rates in low-income sub-Saharan African regions in 2017, 
despite a substantial decline since 1990, which is 
compatible with previous reports.33 However, we observed 
lower death rates in higher SDI countries and territories 
(eg, the lowest rate was in Singapore). These findings are 
expected because most cirrhosis-related deaths can be 
avoided in high-income countries through better access 
to health care and stronger health infrastructure. Notable 
exceptions are countries located in eastern Europe and 
central Asia, where, unlike in other regions, the age-
standardised death rates increased from 1990 to 2017, 
primarily driven by alcohol-related liver disease, which 
has also been reported previously.34 Similarly, in Latin 
American regions, a high proportion of deaths were due 
to alcohol-related liver disease, although age-standardised 
death rates were not as high as those in eastern Europe 
and central Asia. These patterns closely follow the 
distribution of alcohol consumption in these regions.28,30
In western Europe, despite low age-standardised death 
rates, a high proportion of deaths were due to alcohol-
related liver disease. This finding is consistent with 
previous evidence on high alcohol use in these 
regions28,30,34 and demonstrates a need for a systematic 
approach to reducing alcohol use in these countries. To 
this end, in 2010, the member states of WHO reached a 
consensus at the World Health Assembly on a global 
strategy to confront the harmful use of alcohol.35
High-income regions had low age-standardised rates of 
cirrhosis deaths. Most of these regions, including 
Australasia, high-income North America, and western 
Europe, also had low age-standardised prevalences of 
both compensated and decompensated cirrhosis as a 
result of concerted efforts to treat and prevent viral 
hepatitis.34,36 The estimated age-standardised prevalence 
and death rates caused by cirrhosis in this study were 
slightly higher but generally compatible with previous 
reports from the USA and released by the US Centers for 
Disease Control and Prevention.37 The estimated age-
standardised death rates in the UK were also consistent 
with previous reports.38
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The high-income Asia Pacific countries, especially 
Japan and South Korea, had a high but declining age-
standardised prevalence rate of compensated cirrhosis, 
despite having low mortality rates.39 Prevalence trends 
could indicate a high incidence in preceding decades 
followed by a recent decline in mortality because of 
improved health care and access to affordable and 
effective antiviral treatment. Accordingly, in 2005, the 
WHO Western Pacific region set a goal to reduce HBsAg 
seroprevalence in children 5 years of age and older to less 
than 2% by 2012. A supranational goal was selected to 
create a sense of political urgency to establish routine 
immunisation and improve access to health care.39 A 
similar approach might be successful in African and 
other Asian countries, as well as in the region of north 
Africa and the Middle East, to control the incidence of 
hepatitis B; cirrhosis deaths in these regions were mainly 
due to hepatitis B and C.
Southeast Asia had higher age-standardised death 
rates than expected, and south Asia and Oceania had 
modest death rates, but these three regions were among 
those with the lowest age-standardised prevalence of 
com pensated and decompensated cirrhosis. Mortality 
was primarily due to hepatitis B in these regions. The 
low age-standardised prevalence of compensated 
cirrhosis in these regions might be because of a low 
detection rate, whereas the low age-standardised 
prevalence of decom pensated cirrhosis might be 
because of a relatively poor medical infrastructure, 
leading to a short survival time once the cirrhosis starts 
to decompensate.40
In north Africa and the Middle East, alcohol-related liver 
disease constituted the lowest proportion of age-
standardised prevalence and death rates.19 This finding 
could be expected, because alcohol is prohibited in many of 
the countries in this region, which could lead to both 
decreased use and the possibility of under-reporting. 
Instead, hepatitis B and C constitute larger proportions. 
Despite a decrease in age-standardised death rates in this 
region, hepatitis B is still the major cause of cirrhosis 
deaths, and although most countries in these regions have 
nationwide infant vaccination programmes for hepatitis B, 
none have been in place for more than 30 years.41 Most of 
the mortality of hepatitis B is in patients older than 40 years, 
so we expect hepatitis B to remain a major cause of cirrhosis 
death for another decade or two, even in countries with 
good vaccine coverage.
Hepatitis C, by contrast, now has an effective cure, 
which should have an impact much sooner. With the 
increased availability of cheap generic anti-hepatitis C 
virus medicines,42 we expect the death rate for hepatitis C 
to rapidly decrease in the near future, if countries are able 
to meet the goals set by WHO to eliminate the burden of 
hepatitis C by 2030.43 For example, in Egypt, which 
currently has the highest death rate due to hepatitis C,19 we 
expect a rapid decrease in the hepatitis C death rate within 
the next 5–10 years because of an active patient-finding 
and treatment programme enacted by the government in 
2014.44 Australia has also been successful in finding and 
treating patients with hepatitis C and will probably have 
very low hepatitis C death rates in the near future.45
Between 1990 and 2017, we observed a doubling in the 
number of deaths, a more than tripling in prevalent cases 
of decompensated cirrhosis, and a more than doubling 
in prevalent cases of compensated cirrhosis due to 
NASH. Unlike the other four causes studied, NASH was 
the only one not to show a decreasing trend in age-
standardised death rates. The highest proportions of 
deaths due to NASH were in Latin America and north 
Africa and the Middle East, and the lowest was in high-
income Asia Pacific, as previously reported.46 The 
epidemiology of NASH closely follows the distribution of 
overweight and obesity and components of metabolic 
syndrome in these regions.27,47 Because of the absence of 
practical means of preventing or treating NASH and a 
global increase in metabolic syndrome and obesity, we 
should expect an increase in the burden of this disease.16,17
Despite the availability of an effective vaccine for 
hepatitis B for decades, the availability of an effective 
treatment for hepatitis C, and an increase in obesity 
worldwide, the proportional contribution of different 
causes to cirrhosis remained fairly constant between 
1990 and 2017 at the global level. The development of 
cirrhosis and its progression to decompensation takes 
decades, and it might still be too early to see the effects of 
vaccination coverage or increased prevalence of obesity 
and metabolic syndrome.
The limitations of the methods of GBD impose biases 
on our estimates in the current study, as with all GBD 
research. The most important limitation is the low 
availability and low quality of data, although we used 
robust statistical methods to overcome data scarcity in 
countries with low data availability. In these locations, we 
relied on predictive covariates, trends in neighbouring 
countries, or a combination of these. The wide variation 
in the availability of high-quality data across locations is 
reflected in the uncertainty associated with all estimates. 
As a result of lower availability of population-based data 
on the prevalence of cirrhosis, dependence on hospital 
and claims data, and various definitions and diagnostic 
criteria for decompensated and compensated cirrhosis, it 
is possible that both types, especially compensated 
cirrhosis, have been underestimated. We made the 
assumption that patients admitted to hospitals had 
decompensated cirrhosis and that total cases detected 
upon admission constituted all cases of cirrhosis. Of 
note, although ICD-10 codes have been validated for 
overall cirrhosis and chronic liver diseases, detailed codes 
for the five causes have not been fully validated. To 
address this challenge, we combined the aetiological 
models for cirrhosis and liver cancer, as these two diseases 
share the same causes. Aetiological proportion models of 
liver cancer were used as covariates for cirrhosis 
aetiological proportion models. Finally, advances in 
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imaging modalities and the availability of liver biopsy as 
the gold standard for detecting cirrhosis in population-
based studies can considerably improve the accuracy of 
estimations.
Further work is needed to disentangle the separate 
entities that were categorised as other causes in this 
study, including autoimmune hepatitis as a sixth cause 
for cirrhosis. A detailed study on the epidemiology of 
NASH, particularly in north Africa and the Middle East 
and Latin America, is needed because it disproportionately 
affects age-standardised death rate as compared with 
other causes. Future studies should focus on evaluating 
common risk factors, dietary patterns, and screening 
practices affecting the incidence, mortality, and 
prevalence of cirrhosis by age, sex, and race, especially 
among countries and territories with the highest 
numbers of deaths. The financial burden of cirrhosis 
also merits attention in future studies.
In conclusion, the major causes of cirrhosis are 
preventable and treatable; however, setting cost-effective 
policies to prevent and treat cirrhosis requires high-
quality, localised data. GBD provides the most up-to-date 
estimates on the burden of cirrhosis by cause to guide 
policy makers in designing effective preventive plans and 
implementing interventions at national and even 
subnational levels. In line with the Global Health Sector 
Strategy on Viral Hepatitis 2016 to 2021, the Sustainable 
Development Goals, and the WHO Global Strategy to 
Reduce Harmful Use of Alcohol, there is a need to 
implement compre hensive prevention efforts to achieve 
a sustained reduction in cirrhosis burden.
GBD 2017 Cirrhosis Collaborators
Sadaf G Sepanlou, Saeid Safiri, Catherine Bisignano, Kevin S Ikuta, 
Shahin Merat, Mehdi Saberifiroozi, Hossein Poustchi, Derrick Tsoi, 
Danny V Colombara, Amir Abdoli, Rufus Adesoji Adedoyin, 
Mohsen Afarideh, Sutapa Agrawal, Sohail Ahmad, Elham Ahmadian, 
Ehsan Ahmadpour, Tomi Akinyemiju, Chisom Joyqueenet Akunna, 
Vahid Alipour, Amir Almasi-Hashiani, Abdulaziz M Almulhim, 
Rajaa M Al-Raddadi, Nelson Alvis-Guzman, Nahla Hamed Anber, 
Colin Angus, Amir Anoushiravani, Jalal Arabloo, 
Ephrem Mebrahtu Araya, Daniel Asmelash, Bahar Ataeinia, 
Zerihun Ataro, Maha Moh’d Wahbi Atout, Floriane Ausloos, 
Ashish Awasthi, Alaa Badawi, Maciej Banach, 
Diana Fernanda Bejarano Ramirez, Akshaya Srikanth Bhagavathula, 
Neeraj Bhala, Krittika Bhattacharyya, Antonio Biondi, 
Srinivasa Rao Bolla, Archith Boloor, Antonio M Borzì, Zahid A Butt, 
Luis LA Alberto Cámera, Ismael R Campos-Nonato, Félix Carvalho, 
Dinh-Toi Chu, Sheng-Chia Chung, Paolo Angelo Cortesi, Vera M Costa, 
Benjamin C Cowie, Ahmad Daryani, Barbora de Courten, 
Gebre Teklemariam Demoz, Rupak Desai, 
Samath Dhamminda Dharmaratne, Shirin Djalalinia, Hoa Thi Do, 
Fariba Dorostkar, Thomas M Drake, Manisha Dubey, Bruce B Duncan, 
Andem Effiong, Aziz Eftekhari, Aisha Elsharkawy, Arash Etemadi, 
Mohammad Farahmand, Farshad Farzadfar, Eduarda Fernandes, 
Irina Filip, Florian Fischer, Ketema Bizuwork Bizuwork Gebremedhin, 
Birhanu Geta, Syed Amir Gilani, Paramjit Singh Gill, 
Reyna Alma Gutiérrez, Michael Tamene Haile, Arvin Haj-Mirzaian, 
Saeed S Hamid, Milad Hasankhani, Amir Hasanzadeh, 
Maryam Hashemian, Hamid Yimam Hassen, Simon I Hay, 
Khezar Hayat, Behnam Heidari, Andualem Henok, Chi Linh Hoang, 
Mihaela Hostiuc, Sorin Hostiuc, Vivian Chia-rong Hsieh, 
Ehimario U Igumbor, Olayinka Stephen Ilesanmi, 
Seyed Sina Naghibi Irvani, Nader Jafari Balalami, Spencer L James, 
Panniyammakal Jeemon, Ravi Prakash Jha, Jost B Jonas, 
Jacek Jerzy Jozwiak, Ali Kabir, Amir Kasaeian, 
Hagazi Gebremedhin Kassaye, Adane Teshome Kefale, 
Rovshan Khalilov, Muhammad Ali Khan, Ejaz Ahmad Khan, 
Amir Khater, Yun Jin Kim, Ai Koyanagi, Carlo La Vecchia, Lee-Ling Lim, 
Alan D Lopez, Stefan Lorkowski, Paulo A Lotufo, Rafael Lozano, 
Muhammed Magdy Abd El Razek, Hue Thi Mai, Navid Manafi, 
Amir Manafi, Mohammad Ali Mansournia, 
Lorenzo Giovanni Mantovani, Giampiero Mazzaglia, Dhruv Mehta, 
Walter Mendoza, Ritesh G Menezes, Melkamu Merid Mengesha, 
Tuomo J Meretoja, Tomislav Mestrovic, Bartosz Miazgowski, 
Ted R Miller, Erkin M Mirrakhimov, Prasanna Mithra, Babak Moazen, 
Masoud Moghadaszadeh, Abdollah Mohammadian-Hafshejani, 
Shafiu Mohammed, Ali H Mokdad, Pablo A Montero-Zamora, 
Ghobad Moradi, Mukhammad David Naimzada, Vinod Nayak, 
Ionut Negoi, Trang Huyen Nguyen, Richard Ofori-Asenso, In-Hwan Oh, 
Tinuke O Olagunju, Jagadish Rao Padubidri, Keyvan Pakshir, 
Adrian Pana, Mona Pathak, Akram Pourshams, Navid Rabiee, 
Amir Radfar, Alireza Rafiei, Kiana Ramezanzadeh, 
Saleem Muhammad M Rana, Salman Rawaf, David Laith Rawaf, 
Robert C Reiner Jr, Leonardo Roever, Robin Room, 
Gholamreza Roshandel, Saeed Safari, Abdallah M Samy, Juan Sanabria, 
Benn Sartorius, Maria Inês Schmidt, Subramanian Senthilkumaran, 
Masood Ali Shaikh, Mehdi Sharif, Amrollah Sharifi, Mika Shigematsu, 
Jasvinder A Singh, Amin Soheili, Hafiz Ansar Rasul Suleria, 
Berhane Fseha Teklehaimanot, Berhe Etsay Tesfay, Marco Vacante, 
Amir Vahedian-Azimi, Pascual R Valdez, Tommi Juhani Vasankari, 
Giang Thu Vu, Yasir Waheed, Kidu Gidey Weldegwergs, 
Andrea Werdecker, Ronny Westerman, Dawit Zewdu Wondafrash, 
Adam Belay Wondmieneh, Yordanos Gizachew Yeshitila, 
Naohiro Yonemoto, Chuanhua Yu, Zoubida Zaidi, Afshin Zarghi, 
Shira Zelber-Sagi, Kaleab Alemayehu Zewdie, Zhi-Jiang Zhang, 
Xiu-Ju Zhao, Mohsen Naghavi, and Reza Malekzadeh.
Affiliations
Digestive Diseases Research Institute (S G Sepanlou MD, 
Prof S Merat MD, H Poustchi PhD, A Anoushiravani MD, 
Prof A Pourshams MD, G Roshandel PhD, Prof R Malekzadeh MD), 
Digestive Diseases Research Institute, SHARIATI Hospital 
(Prof M Saberifiroozi MD), Department of Epidemiology and 
Biostatistics (M Mansournia PhD), Department of Microbiology 
(A Hasanzadeh PhD), Department of Pharmacology 
(A Haj-Mirzaian MD), Endocrinology and Metabolism Research Center 
(M Afarideh MD, B Heidari MD), Hematology-Oncology and Stem Cell 
Transplantation Research Center (A Kasaeian PhD), Non-Communicable 
Diseases Research Center, Endocrinology and Metabolism Research 
Institute (B Ataeinia MD), Non-communicable Diseases Research Center 
(F Farzadfar MD), School of Public Health (M Farahmand PhD), Tehran 
University of Medical Sciences, Tehran, Iran (A Etemadi PhD); 
Non-Communicable Diseases Research Center (S G Sepanlou MD, 
Prof R Malekzadeh MD), Parasitology and Mycology 
(Prof K Pakshir PhD), Shiraz University of Medical Sciences, Shiraz, 
Iran; Aging Research Institute (S Safiri PhD), Department of 
Community Medicine (S Safiri PhD), Biotechnology Research Center 
(M Moghadaszadeh PhD), Department of Parasitology 
(E Ahmadpour PhD), Department of Pharmacology and Toxicology 
(A Eftekhari PhD), Infectious and Tropical Disease Research Center 
(E Ahmadpour PhD), Molecular Medicine Research Center 
(M Moghadaszadeh PhD), Pharmacology and Toxicology 
(E Ahmadian PhD), School of Nutrition and Food Sciences 
(M Hasankhani MSc), Tabriz University of Medical Sciences, Tabriz, 
Iran; Institute for Health Metrics and Evaluation (C Bisignano MPH, 
K S Ikuta MD, D Tsoi BS, D V Colombara PhD, S D Dharmaratne MD, 
Prof S I Hay FMedSci, S L James MD, Prof R Lozano MD, 
Prof A H Mokdad PhD, R C Reiner Jr PhD, Prof M Naghavi MD), 
Department of Health Metrics Sciences, School of Medicine 
(Prof S I Hay FMedSci, Prof R Lozano MD, Prof A H Mokdad PhD, 
R C Reiner Jr PhD, Prof B Sartorius PhD, Prof M Naghavi MD), Division 
of Allergy and Infectious Diseases (K S Ikuta MD), University of 
Washington, Seattle, WA, USA; Department of Parasitology and 
Mycology (A Abdoli PhD), Jahrom University of Medical Sciences, 
Jahrom, Iran; Department of Medical Rehabilitation 
Articles
www.thelancet.com/gastrohep   Published online January 22, 2020    https://doi.org/10.1016/S2468-1253(19)30349-8 19
(Prof R A Adedoyin PhD), Obafemi Awolowo University, Ile-Ife, Nigeria; 
Public Health Foundation of India, Gurugram, India (S Agrawal PhD, 
A Awasthi PhD); Vital Strategies, Gurugram, India (S Agrawal PhD); 
Department of Clinical Pharmacy (S Ahmad MSc), Faculty of Pharmacy, 
Universiti Teknologi MARA (UiTM) (S Ahmad MSc), MAHSA 
University, Kuala Langat, Malaysia; Department of Physiology 
(R Khalilov PhD), Institute of Radiation Problems of Azerbaijan 
(E Ahmadian PhD), Baku State University, Baku, Azerbaijan; 
Department of Population Health Sciences (T Akinyemiju PhD), Duke 
Global Health Institute (T Akinyemiju PhD), Duke University, Durham, 
NC, USA; Department of Public Health (C J Akunna DMD), The 
Intercountry Centre for Oral Health (ICOH) for Africa, Jos, Nigeria; 
Department of Public Health (C J Akunna DMD), Federal Ministry of 
Health, Garki, Nigeria; Health Management and Economics Research 
Center (V Alipour PhD), Tehran, Iran; Faculty of Allied Medicine 
(F Dorostkar PhD), Health Economics Department (V Alipour PhD), 
Health Management and Economics Research Center (J Arabloo PhD), 
Minimally Invasive Surgery Research Center (A Kabir MD), 
Ophthalmology Department (N Manafi MD), Pars Advanced and 
Minimally Invasive Medical Manners Research Center 
(A Kasaeian PhD), Iran University of Medical Sciences, Tehran, Iran; 
Department of Epidemiology (A Almasi-Hashiani PhD), Arak University 
of Medical Sciences, Arak, Iran; College of Medicine 
(A M Almulhim MBBS), Forensic Medicine Division, Department of 
Pathology, College of Medicine (Prof R G Menezes MD), Imam 
Abdulrahman Bin Faisal University, Dammam, Saudi Arabia; 
Department of Family and Community Medicine 
(Prof R M Al-Raddadi PhD), King Abdulaziz University, Jeddah, Saudi 
Arabia; Grupo de Investigación en Economía de la Salud (GIES) 
(Prof N Alvis-Guzman PhD), University of Cartagena, Cartagena, 
Colombia; Research Group in Hospital Management and Health Policies 
(Prof N Alvis-Guzman PhD), University of the Coast, Barranquilla, 
Colombia; Faculty of Medicine (N H Anber PhD), Mansoura University, 
Mansoura, Egypt (N H Anber PhD); School of Health and Related 
Research (C Angus MSc), University of Sheffield, Sheffield, UK; 
Department of Pharmacy (H G Kassaye MSc), Department of Public 
Health (B F Teklehaimanot MPH, B E Tesfay MPH), Department of 
Pharmacy (E Araya MSc), Adigrat University, Adigrat, Ethiopia; Clinical 
Chemistry Department (D Asmelash MSc), University of Gondar, 
Gondar, Ethiopia; Department of Epidemiology and Biostatistics 
(M Mengesha MPH), Department of Medical Laboratory Science 
(Z Ataro MSc), Haramaya University, Harar, Ethiopia; School of Nursing 
(M M W Atout PhD), University of Nottingham, Amman, Jordan; 
Gastro-enterology Department (F Ausloos MD), University of Liège, 
Liège, Belgium; Public Health Risk Sciences Division (A Badawi PhD), 
Public Health Agency of Canada, Toronto, ON, Canada; Department of 
Nutritional Sciences (A Badawi PhD), University of Toronto, Toronto, 
ON, Canada; Department of Hypertension (Prof M Banach PhD), 
Medical University of Lodz, Lodz, Poland; Polish Mothers’ Memorial 
Hospital Research Institute, Lodz, Poland (Prof M Banach PhD); 
Department of Medicine (D F Bejarano Ramirez BN), El Bosque 
University, Bogotá, Colombia; Transplant Service 
(D F Bejarano Ramirez BN), University Hospital Foundation Santa Fe de 
Bogotá, Bogotá, Colombia; Internal Medicine 
(A S Bhagavathula PharmD), United Arab Emirates University, Al Ain, 
United Arab Emirates; Social and Clinical Pharmacy 
(A S Bhagavathula PharmD), Charles University, Hradec Kralove, Czech 
Republic; Institutes of Applied Health Research and Translational 
Medicine (N Bhala DPhil), Queen Elizabeth Hospital Birmingham, 
Birmingham, UK; IAHR/ITM (N Bhala DPhil), University of 
Birmingham, Birmingham, UK; Department of Statistical and 
Computational Genomics (K Bhattacharyya MSc), National Institute of 
Biomedical Genomics, Kalyani, India; Department of Statistics 
(K Bhattacharyya MSc), University of Calcutta, Kolkata, India; 
Department of General Surgery and Medical-Surgical Specialties 
(Prof A Biondi PhD, A M Borzì MD, M Vacante PhD), University of 
Catania, Catania, Italy; Department of Biomedical Sciences 
(S R Bolla PhD), Nazarbayev University, Nur-Sultan city, Kazakhstan; 
Community Medicine (P Mithra MD), Department of Forensic Medicine 
and Toxicology (V Nayak MD), Department of Forensic Medicine, 
Kasturba Medical College (J Padubidri MD), Internal Medicine 
(A Boloor MD), Manipal Academy of Higher Education, Mangalore, 
India; School of Public Health and Health Systems (Z A Butt PhD), 
University of Waterloo, Waterloo, ON, Canada; Al Shifa School of Public 
Health (Z A Butt PhD), Al Shifa Trust Eye Hospital, Rawalpindi, 
Pakistan; Medicina Interna (Prof L L A Cámera MD), Hospital Italiano 
de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina; 
Comisión Directiva (Prof L L A Cámera MD), Argentine Society of 
Medicine, Ciudad Autonoma Buenos Aires, Argentina 
(Prof P R Valdez MEd); Center for Health Systems Research 
(P A Montero-Zamora MSc), National Institute of Public Health, 
Cuernavaca, Mexico (I R Campos-Nonato PhD); REQUIMTE/LAQV 
(Prof E Fernandes PhD), UCIBIO (Prof F Carvalho PhD), UCIBIO, 
REQUIMTE, Laboratory of Toxicology, Faculty of Pharmacy 
(Prof V M Costa PharmD), University of Porto, Porto, Portugal; Faculty 
of Biology (D Chu PhD), Hanoi National University of Education, Hanoi, 
Vietnam; Department of Health Informatics (S Chung PhD), University 
College London, London, UK; Health Data Research UK, London, UK 
(S Chung PhD); Department of Medicine (G Mazzaglia PhD), School of 
Medicine and Surgery (P A Cortesi PhD, Prof L G Mantovani DSc), 
University of Milan Bicocca, Monza, Italy; WHO Collaborating Centre 
for Viral Hepatitis (B C Cowie PhD), The Peter Doherty Institute for 
Infection and Immunity, Melbourne, VIC, Australia; Department of 
Agriculture and Food Systems (H Suleria PhD), Department of Medicine 
(B C Cowie PhD), School of Population and Global Health 
(Prof A D Lopez PhD), University of Melbourne, Parkville, VIC, 
Australia; Department of Immunology (Prof A Rafiei PhD), Molecular 
and Cell Biology Research Center (Prof A Rafiei PhD), Toxoplasmosis 
Research Center (Prof A Daryani PhD), Mazandaran University of 
Medical Sciences, Sari, Iran; Centre of Cardiovascular Research and 
Education in Therapeutics (R Ofori-Asenso MSc), Monash Centre for 
Health Research and Implementation (B de Courten PhD), Monash 
University, Melbourne, VIC, Australia; Department of Diabetes and 
Vascular Medicine (B de Courten PhD), Monash Health, Melbourne, 
VIC, Australia; School of Pharmacy (G T Demoz MPharm), Aksum 
University, Aksum, Ethiopia; Department of Pharmacology 
(D Z Wondafrash MS), Nursing Department (K B B Gebremedhin MSc), 
Addis Ababa University, Addis Ababa, Ethiopia (G T Demoz MPharm, 
A B Wondmieneh MSc); Division of Cardiology (R Desai MBBS), Atlanta 
Veterans Affairs Medical Center, Decatur, GA, USA; Department of 
Community Medicine (S D Dharmaratne MD), University of Peradeniya, 
Peradeniya, Sri Lanka; Deputy of Research and Technology 
(S Djalalinia PhD), Ministry of Health and Medical Education, Tehran, 
Iran; Institute for Global Health Innovations (H T Do MD, 
H T Mai MPH), Duy Tan University, Hanoi, Vietnam; Department of 
Clinical Surgery (T M Drake MD), University of Edinburgh, Edinburgh, 
UK; World Food Programme, New Delhi, India (M Dubey PhD); 
Postgraduate Program in Epidemiology (B B Duncan MD, 
Prof M I Schmidt PhD), Federal University of Rio Grande do Sul, Porto 
Alegre, Brazil; Clinical Epidemiology and Biostatistics (A Effiong MB), 
University of Newcastle, Newcastle, NSW, Australia; Department of 
Microbiology (A Hasanzadeh PhD), Pharmacology and Toxicology 
Department (A Eftekhari PhD), Maragheh University of Medical 
Sciences, Maragheh, Iran; Endemic Medicine and 
Hepatogastroentrology Department (A Elsharkawy MD), Cairo 
University, Cairo, Egypt; Division of Cancer Epidemiology and Genetics 
(A Etemadi PhD), National Cancer Institute, Bethesda, MD, USA; 
Psychiatry Department (I Filip MD), Kaiser Permanente, Fontana, CA, 
USA; College of Graduate Health Sciences (A Radfar MD), School of 
Health Sciences (I Filip MD), A.T. Still University, Mesa, AZ, USA; 
Department of Population Medicine and Health Services Research 
(F Fischer PhD), Bielefeld University, Bielefeld, Germany; Nursing 
(A B Wondmieneh MSc), Pharmacy (B Geta MSc), Wollo University, 
Dessie, Ethiopia; Faculty of Allied Health Sciences (Prof S Gilani PhD), 
The University of Lahore, Lahore, Pakistan; Chairman BOG 
(Prof S Gilani PhD), Afro-Asian Institute, Lahore, Pakistan; Unit of 
Academic Primary Care (Prof P S Gill DM), University of Warwick, 
Coventry, UK; Department of Epidemiology and Psychosocial Research 
(R A Gutiérrez PhD), Ramón de la Fuente Muñiz National Institute of 
Psychiatry , Mexico City, Mexico; Department of Nursing 
(M T Haile MSc), St Paul’s Hospital Millennium Medical College, Addis 
Ababa, Ethiopia; Department of Medicinal and Pharmaceutical 
Articles
20 www.thelancet.com/gastrohep   Published online January 22, 2020    https://doi.org/10.1016/S2468-1253(19)30349-8
Chemistry (Prof A Zarghi PhD), Department of Pharmacology 
(K Ramezanzadeh PharmD), Emergency Department (S Safari MD), 
Obesity Research Center (A Haj-Mirzaian MD), Research Institute for 
Endocrine Sciences (S N Irvani MD), Shahid Beheshti University of 
Medical Sciences, Tehran, Iran; Medicine (Prof S S Hamid FRCP), 
Aga Khan University, Karachi, Pakistan; Department of Biology 
(M Hashemian PhD), Utica College, Utica, NY, USA; Department of 
Public Health (H Y Hassen MPH, A Henok MPH), Pharmacy 
Department (A T Kefale MSc), Mizan-Tepi University, Tepi, Ethiopia; 
Unit of Epidemiology and Social Medicine (H Y Hassen MPH), 
University Hospital Antwerp, Wilrijk, Belgium; Institute of 
Pharmaceutical Sciences (K Hayat MS), University of Veterinary and 
Animal Sciences, Lahore, Pakistan; Department of Pharmacy 
Administration and Clinical Pharmacy (K Hayat MS), Xian Jiaotong 
University, Xian, China; Center of Excellence in Behavioral Medicine 
(C L Hoang BMedSc, T H Nguyen BMedSc, G T Vu BA), Nguyen Tat 
Thanh University, Ho Chi Minh City, Vietnam; Department of General 
Surgery (M Hostiuc PhD), Faculty of Dentistry, Department of Legal 
Medicine and Bioethics (S Hostiuc PhD), General Surgery 
(I Negoi PhD), Carol Davila University of Medicine and Pharmacy, 
Bucharest, Romania; Department of Internal Medicine 
(M Hostiuc PhD), Bucharest Emergency Hospital, Bucharest, Romania; 
Clinical Legal Medicine Department (S Hostiuc PhD), National Institute 
of Legal Medicine Mina Minovici, Bucharest, Romania; Department of 
Health Services Administration (V Hsieh PhD), China Medical 
University, Taichung, Taiwan; School of Public Health 
(Prof E U Igumbor PhD), University of the Western Cape, Cape Town, 
South Africa; Department of Public Health (Prof E U Igumbor PhD), 
Walter Sisulu University, Mthatha, South Africa; Department of 
Community Medicine (O S Ilesanmi PhD), University of Ibadan, Ibadan, 
Nigeria; Department of Psychosis (N Jafari Balalami PhD), Babol 
Noshirvani University of Technology, Babol, Iran; Achutha Menon 
Centre for Health Science Studies (P Jeemon PhD), Sree Chitra Tirunal 
Institute for Medical Sciences and Technology, Trivandrum, India; 
Department of Community Medicine (R P Jha MSc), Banaras Hindu 
University, Varanasi, India; Department of Ophthalmology 
(Prof J B Jonas MD), Heidelberg Institute of Global Health (HIGH) 
(B Moazen MSc, S Mohammed PhD), Heidelberg University, 
Mannheim, Germany; Beijing Institute of Ophthalmology, Beijing 
Ophthalmology & Visual Science Key Laboratory (Prof J B Jonas MD), 
Beijing Tongren Hospital, Beijing, China; Department of Family 
Medicine and Public Health (J J Jozwiak PhD), University of Opole, 
Opole, Poland; Department of Medicine (Prof J A Singh MD), University 
of Alabama at Birmingham, Birmingham, AL, USA (M Khan MD); 
University of Tennessee, Knoxville, TN, USA (M Khan MD); 
Epidemiology and Biostatistics Department (E A Khan MPH), Health 
Services Academy, Islamabad, Pakistan; Internal Medicine and 
Gastroenterology Department (A Khater MD), National Hepatology and 
Tropical Research Institute, Cairo, Egypt; School of Medicine 
(Y Kim PhD), Xiamen University Malaysia, Sepang, Malaysia; 
CIBERSAM (A Koyanagi MD), San Juan de Dios Sanitary Park, Sant Boi 
de Llobregat, Spain; Catalan Institution for Research and Advanced 
Studies (ICREA), Barcelona, Spain (A Koyanagi MD); Clinical Medicine 
and Community Health (Prof C La Vecchia MD), University of Milan, 
Milano, Italy; Department of Medicine (L Lim MRCP), University of 
Malaya, Kuala Lumpur, Malaysia; Department of Medicine and 
Therapeutics (L Lim MRCP), The Chinese University of Hong Kong, 
Shatin, Hong Kong, China; Institute of Nutrition 
(Prof S Lorkowski PhD), Friedrich Schiller University Jena, Jena, 
Germany; Competence Cluster for Nutrition and Cardiovascular Health 
(nutriCARD), Jena, Germany (Prof S Lorkowski PhD); Department of 
Medicine (Prof P A Lotufo DrPH), University of São Paulo, São Paulo, 
Brazil; Ophthalmology Department (M Magdy Abd El Razek MB), 
Aswan Faculty of Medicine, Aswan, Egypt; Ophthalmology Department 
(N Manafi MD), University of Manitoba, Winnipeg, MB, Canada; 
Department of Surgery (A Manafi MD), University of Virginia, 
Charlottesville, VA, USA; Value-Based Healthcare Unit 
(Prof L G Mantovani DSc), IRCCS MultiMedica, Sesto San Giovanni, 
Italy; Division of Gastroenterology and Hepatobiliary disease 
(D Mehta MD), New York Medical College, Valhalla, NY, USA; Peru 
Country Office (W Mendoza MD), United Nations Population Fund 
(UNFPA), Lima, Peru; Breast Surgery Unit (T J Meretoja MD), Helsinki 
University Hospital, Helsinki, Finland; University of Helsinki, Helsinki, 
Finland (T J Meretoja MD); Clinical Microbiology and Parasitology Unit 
(T Mestrovic PhD), Zora Profozic Polyclinic, Zagreb, Croatia; University 
Centre Varazdin (T Mestrovic PhD), University North, Varazdin, Croatia; 
Center for Innovation in Medical Education (B Miazgowski MD), 
Pomeranian Medical University, Szczecin, Poland (B Miazgowski MD); 
Pacific Institute for Research & Evaluation, Calverton, MD, USA 
(T R Miller PhD); School of Public Health (T R Miller PhD), Curtin 
University, Perth, WA, Australia; Faculty of Internal Medicine 
(Prof E M Mirrakhimov MD), Kyrgyz State Medical Academy, Bishkek, 
Kyrgyzstan; Department of Atherosclerosis and Coronary Heart Disease 
(Prof E M Mirrakhimov MD), National Center of Cardiology and Internal 
Disease, Bishkek, Kyrgyzstan; Institute of Addiction Research (ISFF) 
(B Moazen MSc), Frankfurt University of Applied Sciences, Frankfurt, 
Germany; Department of Epidemiology and Biostatistics 
(A Mohammadian-Hafshejani PhD), Shahrekord University of Medical 
Sciences, Shahrekord, Iran; Health Systems and Policy Research Unit 
(S Mohammed PhD), Ahmadu Bello University, Zaria, Nigeria; 
Department of Public Health Sciences (P A Montero-Zamora MSc), 
University of Miami, Miami, FL, USA; Department of Epidemiology and 
Biostatistics (G Moradi PhD), Social Determinants of Health Research 
Center (G Moradi PhD), Kurdistan University of Medical Sciences, 
Sanandaj, Iran; Laboratory of Public Health Indicators Analysis and 
Health Digitalization (M Naimzada MD), Moscow Institute of Physics 
and Technology, Dolgoprudny, Russia; Experimental Surgery and 
Oncology Laboratory (M Naimzada MD), Kursk State Medical University 
of the Ministry of Health of the Russian Federation, Kursk, Russia; 
General Surgery (I Negoi PhD), Emergency Hospital of Bucharest, 
Bucharest, Romania; Independent Consultant, Accra, Ghana 
(R Ofori-Asenso MSc); Department of Preventive Medicine (I Oh PhD), 
Kyung Hee University, Dongdaemun-gu, South Korea; Department of 
Pathology and Molecular Medicine (T O Olagunju MD), McMaster 
University, Hamilton, ON, Canada; Department of Statistics and 
Econometrics (A Pana MD), Bucharest University of Economic Studies, 
Bucharest, Romania; Center for Health Outcomes & Evaluation, 
Bucharest, Romania (A Pana MD); Research & Publication Cell 
(M Pathak PhD), Kalinga Institute of Medical Sciences, Bhubaneswar, 
Bhubaneswar, India; Department of Chemistry (N Rabiee PhD), Sharif 
University of Technology, Tehran, Iran; College of Medicine 
(A Radfar MD), University of Central Florida, Orlando, FL, USA; 
University Institute of Public Health (Prof S M M Rana PhD), University 
of Lahore, Lahore, Pakistan; Public Health Department 
(Prof S M M Rana PhD), University of Health Sciences, Lahore, 
Pakistan; Department of Primary Care and Public Health 
(Prof S Rawaf MD), WHO Collaborating Centre for Public Health 
Education and Training (D L Rawaf MD), Imperial College London, 
London, UK; Academic Public Health Department (Prof S Rawaf MD), 
Public Health England, London, UK; University College London 
Hospitals, London, UK (D L Rawaf MD); Department of Clinical 
Research (L Roever PhD), Federal University of Uberlândia, Uberlândia, 
Brazil; Centre for Alcohol Policy Research (Prof R Room PhD), La Trobe 
University, Melbourne, VIC, Australia; Centre for Social Research on 
Alcohol and Drugs (Prof R Room PhD), Stockholm University, 
Stockholm, Sweden; Golestan Research Center of Gastroenterology and 
Hepatology (G Roshandel PhD), Golestan Research Center of 
Gastroenterology and Hepatology (GRCGH) (A Sharifi PhD), Golestan 
University of Medical Sciences, Gorgan, Iran; Department of 
Entomology (A M Samy PhD), Ain Shams University, Cairo, Egypt; 
Department of Surgery (Prof J Sanabria MD), Marshall University, 
Huntington, WV, USA; Department of Nutrition and Preventive 
Medicine (Prof J Sanabria MD), Case Western Reserve University, 
Cleveland, OH, USA; Faculty of Infectious and Tropical Diseases 
(Prof B Sartorius PhD), London School of Hygiene & Tropical Medicine, 
London, UK; Emergency Department (S Senthilkumaran MD), Manian 
Medical Centre, Erode, India; Department of Basic Sciences 
(Prof M Sharif PhD), Department of Laboratory Sciences 
(Prof M Sharif PhD), Islamic Azad University, Sari, Iran; Independent 
Consultant, Sindh, Pakistan (M A Shaikh MD); National Institute of 
Infectious Diseases, Tokyo, Japan (M Shigematsu PhD); Medicine 
Service (Prof J A Singh MD), US Department of Veterans Affairs (VA), 
Articles
www.thelancet.com/gastrohep   Published online January 22, 2020    https://doi.org/10.1016/S2468-1253(19)30349-8 21
Birmingham, AL, USA; Medical Surgical Nursing Department 
(A Soheili PhD), Urmia University of Medical Science, Urmia, Iran; 
Emergency Nursing Department (A Soheili PhD), Semnan University of 
Medical Sciences, Iran; Trauma Research Center, Nursing Facility 
(A Vahedian-Azimi PhD), Baqiyatallah University of Medical Sciences, 
Tehran, Iran; Velez Sarsfield Hospital, Buenos Aires, Argentina 
(Prof P R Valdez MEd); UKK Institute, Tampere, Finland 
(Prof T J Vasankari MD); Foundation University Medical College 
(Y Waheed PhD), Foundation University, Islamabad, Pakistan; Clinical 
Pharmacy Unit (K G Weldegwergs MSc), Department of Pharmacology 
and Toxicology, College of Health Sciences, School of Pharmacy 
(D Z Wondafrash MS), Pharmacy (K A Zewdie MSc), Mekelle University, 
Mekelle, Ethiopia; Competence Center of Mortality-Follow-Up, German 
National Cohort (R Westerman DSc), Demographic Change and Ageing 
Research Area (A Werdecker PhD), Federal Institute for Population 
Research, Wiesbaden, Germany; Center of Population and Health, 
Wiesbaden, Germany (A Werdecker PhD); Nursing (Y G Yeshitila MSc), 
Arba Minch University, Arba Minch, Ethiopia; Department of 
Psychopharmacology (N Yonemoto MPH), National Center of Neurology 
and Psychiatry, Tokyo, Japan; Department of Epidemiology and 
Biostatistics (Prof C Yu PhD), Department of Preventive Medicine 
(Z Zhang PhD), Global Health Institute (Prof C Yu PhD), Wuhan 
University, Wuhan, China; Department of Epidemiology 
(Prof Z Zaidi PhD), University Hospital of Setif, Setif, Algeria; School of 
Public Health, Faculty of Social Welfare and Health Sciences 
(Prof S Zelber-Sagi PhD), University of Haifa, Haifa, Israel; 
Gastroenterology Department (Prof S Zelber-Sagi PhD), Tel Aviv 
Saurasky Medical Center, Tel Aviv, Israel; and Wuhan Polytechnic 
University, Wuhan, China (X Zhao PhD).
Contributors
SGS, SM, SS, AP, MS, and HP prepared the first draft. RM, MSF, DC, 
and MN provided overall guidance. RM, SGS, SM, SS, and KS managed 
the project. SGS, SS, and DT analysed data. RM, SGS, SM, MSF, and CB 
finalised the manuscript on the basis of comments from other authors 
and reviewer feedback. All other authors provided data, developed 
models, reviewed results, provided guidance on methods, or reviewed 
and contributed to the manuscript. 
Declaration of interests
SLJ reports grants from Sanofi Pasteur, outside the submitted work. 
PJ reports receiving the Wellcome Trust/DBT India Alliance Fellowship 
[grant number IA/CPHI/14/1/501497]. JJJ reports personal fees from 
Alab Laboratoria and Teva Polska, and non-financial support from 
Servier, Microlife, Superpharm, and Medicover, outside the submitted 
work. SL reports personal fees from Akcea Therapeutics, Amgen, 
Berlin-Chemie, Boehringer Ingelheim Pharma, Daiichi Sankyo, MSD 
Sharp & Dohme, Novo Nordisk, Sanofi-Aventis, Synlab, Unilever, and 
Upfield, as well as non-financial support from Preventicus outside the 
submitted work. PAL reports grants from Fundação Vale, Rio de Janeiro, 
Brazil. JAS is on the steering committee of OMERACT, an international 
organization that develops measures for clinical trials and receives 
funding from 12 pharmaceutical companies, serves on the FDA Arthritis 
Advisory Committee, is a member of the Veterans Affairs Rheumatology 
Field Advisory Committee, is the editor and the Director of the UAB 
Cochrane Musculoskeletal Group Satellite Center on Network 
Meta-analysis, is on the speaker’s bureau of Simply Speaking, consults 
with Crealta/Horizon, Medisys, Fidia, UBM LLC, Trio health, Medscape, 
WebMD, Clinical Care options, Clearview healthcare partners, Putnam 
associates, Spherix, Practice Point communications, the National 
Institutes of Health and the American College of Rheumatology, and has 
stock options in Amarin Pharmaceuticals and Viking Pharmaceuticals. 
All other authors declare no competing interests.
Acknowledgments
This study is funded by the Bill & Melinda Gates Foundation. AB is 
supported by the Public Health Agency of Canada. LAC acknowledges 
the Argentine Society of Medicine for supporting our research. 
FC acknowledges support through Portuguese national funds 
(UID/MULTI/04378/2019 and UID/QUI/50006/2019 with FCT/MCTES). 
VMC acknowledges her grant (SFRH/BHD/110001/2015), received by 
Portuguese national funds through Fundaco para a Ciencia e Tecnologia 
(FCT), IP, under the Norma Transitaria DL57/2016/CP1334/CT0006. 
SLJ works on an influenza/RSV grant funded by Sanofi Pasteur. PJ is 
supported by Wellcome Trust/DBT India Alliance Fellowship [grant 
number IA/CPHI/14/1/501497]. YJK acknowledges support from Xiamen 
University Malaysia Research Fund (Grant No. XMUMRF/2018-2/
ITCM/0001). SL acknowledges institutional support from the 
Competence Cluster for Nutrition and Cardiovascular Health 
(nutriCARD) Halle-Jena-Leipzig (Germany; German Federal Ministry of 
Education and Research; grant agreement number 01EA1808A). WM is 
currently Program Analyst Population and Development at the United 
Nations Population Fund-UNFPA Country Office in Peru, which not 
necessarily endorses this study. PM-Z acknowledges the support 
awarded in 2015 by the National Council of Science and Technology of 
Mexico, the Inter-American Development Bank, the Organization of 
American States, and the National Council for Scientific and 
Technological Research of Costa Rica for offering them a postgraduate 
scholarship to be able to participate in the Global Burden of Disease 
technical training celebrated in Greece. AMS was supported by a 
fellowship from the Egyptian Fulbright Mission Program (EFMP).
Editorial note: The Lancet Group takes a neutral position with respect 
to territorial claims in published maps and institutional affiliations.
References
1 Roth GA, Abate D, Abate KH, et al. Global, regional, and national 
age-sex-specific mortality for 282 causes of death in 195 countries 
and territories, 1980–2017: a systematic analysis for the Global 
Burden of Disease Study 2017. Lancet 2018; 392: 1736–88.
2 Anthony PP, Ishak KG, Nayak NC, Poulsen HE, Scheuer PJ, 
Sobin LH. The morphology of cirrhosis. Recommendations on 
definition, nomenclature, and classification by a working group 
sponsored by the World Health Organization. J Clin Pathol 1978; 
31: 395–414.
3 Fleming KM, Aithal GP, Card TR, West J. The rate of 
decompensation and clinical progression of disease in people with 
cirrhosis: a cohort study. Aliment Pharmacol Ther 2010; 
32: 1343–50.
4 Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure 
is a distinct syndrome that develops in patients with acute 
decompensation of cirrhosis. Gastroenterology 2013; 
144: 1426–37.e1–9.
5 D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and 
prognostic indicators of survival in cirrhosis: a systematic review 
of 118 studies. J Hepatol 2006; 44: 217–31.
6 Fleming KM, Aithal GP, Card TR, West J. All-cause mortality in 
people with cirrhosis compared with the general population: 
a population-based cohort study. Liver Int 2012; 32: 79–84.
7 Ge PS, Runyon BA. Treatment of patients with cirrhosis. 
N Engl J Med 2016; 375: 767–77.
8 Arthur MJ. Reversibility of liver fibrosis and cirrhosis following 
treatment for hepatitis C. Gastroenterology 2002; 122: 1525–28.
9 Czaja AJ. Review article: the prevention and reversal of hepatic 
fibrosis in autoimmune hepatitis. Aliment Pharmacol Ther 2014; 
39: 385–406.
10 Sohrabpour AA, Mohamadnejad M, Malekzadeh R. Review article: 
the reversibility of cirrhosis. Aliment Pharmacol Ther 2012; 
36: 824–32.
11 Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008; 371: 838–51.
12 Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver 
diseases in the world. J Hepatol 2019; 70: 151–71.
13 Asrani SK, Larson JJ, Yawn B, Therneau TM, Kim WR. 
Underestimation of liver-related mortality in the United States. 
Gastroenterology 2013; 145: 375–82.e1–2.
14 Beste LA, Leipertz SL, Green PK, Dominitz JA, Ross D, 
Ioannou GN. Trends in burden of cirrhosis and hepatocellular 
carcinoma by underlying liver disease in US veterans, 2001–2013. 
Gastroenterology 2015; 149: 1471–82.e5.
15 Tsochatzis EA, Bosch J, Burroughs AK. Future treatments of 
cirrhosis. Expert Rev Gastroenterol Hepatol 2014; 8: 571–81.
16 Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. 
Global epidemiology of nonalcoholic fatty liver disease: meta-
analytic assessment of prevalence, incidence, and outcomes. 
Hepatology 2016; 64: 73–84.
17 Diehl AM, Day C. Cause, pathogenesis, and treatment of 
nonalcoholic steatohepatitis. N Engl J Med 2017; 377: 2063–72.
Articles
22 www.thelancet.com/gastrohep   Published online January 22, 2020    https://doi.org/10.1016/S2468-1253(19)30349-8
18 La Vecchia C, Levi F, Lucchini F, Franceschi S, Negri E. Worldwide 
patterns and trends in mortality from liver cirrhosis, 1955 to 1990. 
Ann Epidemiol 1994; 4: 480–86.
19 Mokdad AA, Lopez AD, Shahraz S, et al. Liver cirrhosis mortality 
in 187 countries between 1980 and 2010: a systematic analysis. 
BMC Med 2014; 12: 145.
20 James SL, Abate D, Abate KH, et al. Global, regional, and national 
incidence, prevalence, and years lived with disability for 
354 diseases and injuries for 195 countries and territories, 
1990–2017: a systematic analysis for the Global Burden of Disease 
Study 2017. Lancet 2018; 392: 1789–858.
21 Kyu HH, Abate D, Abate KH, et al. Global, regional, and national 
disability-adjusted life-years (DALYs) for 359 diseases and injuries 
and healthy life expectancy (HALE) for 195 countries and territories, 
1990–2017: a systematic analysis for the Global Burden of Disease 
Study 2017. Lancet 2018; 392: 1859–922.
22 Stanaway JD, Afshin A, Gakidou E, et al. Global, regional, 
and national comparative risk assessment of 84 behavioural, 
environmental and occupational, and metabolic risks or clusters 
of risks for 195 countries and territories, 1990–2017: a systematic 
analysis for the Global Burden of Disease Study 2017. Lancet 2018; 
392: 1923–94.
23 Lapointe-Shaw L, Georgie F, Carlone D, et al. Identifying cirrhosis, 
decompensated cirrhosis and hepatocellular carcinoma in health 
administrative data: a validation study. PLoS One 2018; 
13: e0201120.
24 Mapakshi S, Kramer JR, Richardson P, El-Serag HB, Kanwal F. 
Positive predictive value of International Classification of Diseases, 
10th revision, codes for cirrhosis and its related complications. 
Clin Gastroenterol Hepatol 2018; 16: 1677–78.
25 Foreman KJ, Lozano R, Lopez AD, Murray CJ. Modeling causes of 
death: an integrated approach using CODEm. Popul Health Metr 
2012; 10: 1.
26 Murray CJL, Callender CSKH, Kulikoff XR, et al. Population and 
fertility by age and sex for 195 countries and territories, 1950–2017: 
a systematic analysis for the Global Burden of Disease Study 2017. 
Lancet 2018; 392: 1995–2051.
27 Afshin A, Forouzanfar MH, Reitsma MB, et al. Health effects of 
overweight and obesity in 195 countries over 25 years. N Engl J Med 
2017; 377: 13–27.
28 GBD 2016 Alcohol Collaborators. Alcohol use and burden for 
195 countries and territories, 1990–2016: a systematic analysis for 
the Global Burden of Disease Study 2016. Lancet 2018; 392: 1015–35.
29 Guy J, Peters MG. Liver disease in women: the influence of gender 
on epidemiology, natural history, and patient outcomes. 
Gastroenterol Hepatol 2013; 9: 633–39.
30 Zatoński WA, Sulkowska U, Mańczuk M, et al. Liver cirrhosis 
mortality in Europe, with special attention to Central and Eastern 
Europe. Eur Addict Res 2010; 16: 193–201.
31 Flemming JA, Dewit Y, Mah JM, Saperia J, Groome PA, Booth CM. 
Incidence of cirrhosis in young birth cohorts in Canada from 1997 
to 2016: a retrospective population-based study. 
Lancet Gastroenterol Hepatol 2019; 4: 217–26.
32 Tapper EB, Parikh ND. Mortality due to cirrhosis and liver cancer 
in the United States, 1999–2016: observational study. BMJ 2018; 
362: k2817.
33 Vento S, Dzudzor B, Cainelli F, Tachi K. Liver cirrhosis in 
sub-Saharan Africa: neglected, yet important. Lancet Glob Health 
2018; 6: e1060–61.
34 Liangpunsakul S, Haber P, McCaughan GW. Alcoholic liver disease 
in Asia, Europe, and North America. Gastroenterology 2016; 
150: 1786–97.
35 WHO. Global strategy to reduce the harmful use of alcohol. 2010. 
https://www.who.int/substance_abuse/msbalcstragegy.pdf 
(accessed Sept 22, 2019).
36 Hatzakis A, Wait S, Bruix J, et al. The state of hepatitis B and C in 
Europe: report from the hepatitis B and C summit conference. 
J Viral Hepat 2011; 18 (suppl 1): 1–16.
37 Centers for Disease Control and Prevention. Chronic liver disease 
and cirrhosis mortality by state. January, 2019. https://www.cdc.gov/
nchs/pressroom/sosmap/liver_disease_mortality/liver_disease.htm 
(accessed Sept 22, 2019).
38 Ratib S, West J, Fleming KM. Liver cirrhosis in England—
an observational study: are we measuring its burden occurrence 
correctly? BMJ Open 2017; 7: e013752.
39 Rani M, Yang B, Nesbit R. Hepatitis B control by 2012 in the WHO 
Western Pacific Region: rationale and implications. 
Bull World Health Organ 2009; 87: 707–13.
40 WHO. Viral hepatitis in the WHO South-East Asia Region. 2011. 
https://apps.who.int/iris/handle/10665/206521 (accessed 
Sept 22, 2019).
41 WHO. Global hepatitis report, 2017. April, 2017. https://www.who.
int/hepatitis/publications/global-hepatitis-report2017/en (accessed 
Sept 22, 2019).
42 Freeman JA, Hill A. The use of generic medications for hepatitis C. 
Liver Int 2016; 36: 929–32.
43 WHO. Combating hepatitis B and C to reach elimination by 2030. 
May, 2016. https://apps.who.int/iris/bitstream/
handle/10665/206453/WHO_HIV_2016·04_eng.pdf?sequence=1 
(accessed Sept 22, 2019).
44 Elsharkawy A, El-Raziky M, El-Akel W, et al. Planning and 
prioritizing direct-acting antivirals treatment for HCV patients 
in countries with limited resources: lessons from the Egyptian 
experience. J Hepatol 2018; 68: 691–98.
45 Waheed Y, Siddiq M, Jamil Z, Najmi MH. Hepatitis elimination 
by 2030: progress and challenges. World J Gastroenterol 2018; 
24: 4959–61.
46 Younossi ZM. The epidemiology of nonalcoholic steatohepatitis. 
Clin Liver Dis 2018; 11: 92–94.
47 Pinto Marques Souza de Oliveira C, Pinchemel Cotrim H, 
Arrese M. Nonalcoholic fatty liver disease risk factors in Latin 
American populations: current scenario and perspectives. 
Clin Liver Dis 2019; 13: 39–42.
